{"id":16099,"date":"2025-07-15T09:02:37","date_gmt":"2025-07-15T06:02:37","guid":{"rendered":"https:\/\/medicalpointinternational.com\/%d8%a7%d9%84%d8%a3%d8%b7%d8%a8%d8%a7%d8%a1\/%d8%a7%d9%84%d8%a8%d8%b1%d9%88%d9%81%d9%8a%d8%b3%d9%88%d8%b1-%d8%b3%d8%b1%d9%83%d8%a7%d9%86-%d8%a3%d9%88%d8%b2%d8%a7%d9%83%d8%a8%d8%a7%d8%b4\/"},"modified":"2025-11-21T13:42:53","modified_gmt":"2025-11-21T10:42:53","slug":"%d8%a7%d9%84%d8%a8%d8%b1%d9%88%d9%81%d9%8a%d8%b3%d9%88%d8%b1-%d8%b3%d8%b1%d9%83%d8%a7%d9%86-%d8%a3%d9%88%d8%b2%d8%a7%d9%83%d8%a8%d8%a7%d8%b4","status":"publish","type":"page","link":"https:\/\/medicalpointinternational.com\/ar\/%d8%a7%d9%84%d8%a3%d8%b7%d8%a8%d8%a7%d8%a1\/%d8%a7%d9%84%d8%a8%d8%b1%d9%88%d9%81%d9%8a%d8%b3%d9%88%d8%b1-%d8%b3%d8%b1%d9%83%d8%a7%d9%86-%d8%a3%d9%88%d8%b2%d8%a7%d9%83%d8%a8%d8%a7%d8%b4\/","title":{"rendered":"\u0627\u0644\u0628\u0631\u0648\u0641\u064a\u0633\u0648\u0631 \u0633\u0631\u0643\u0627\u0646 \u0623\u0648\u0632\u0627\u0643\u0628\u0627\u0634"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><div data-elementor-type=\"wp-page\" data-elementor-id=\"16099\" class=\"elementor elementor-16099 elementor-2625\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-45f980e4 e-flex e-con-boxed e-con e-parent\" data-id=\"45f980e4\" data-element_type=\"container\" data-settings='{\"background_background\":\"slideshow\",\"background_slideshow_gallery\":[{\"id\":1509,\"url\":\"https:\\\/\\\/medicalpointinternational.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/MedicalPoint-International-Hospital-About-Us-Pic.webp\"}],\"background_slideshow_loop\":\"yes\",\"background_slideshow_slide_duration\":5000,\"background_slideshow_slide_transition\":\"fade\",\"background_slideshow_transition_duration\":500}'>\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-74a70ce5 e-con-full e-flex e-con e-child\" data-id=\"74a70ce5\" data-element_type=\"container\" data-settings='{\"background_background\":\"classic\"}'>\n\t\t<div class=\"elementor-element elementor-element-5bb0b234 e-con-full e-flex e-con e-child\" data-id=\"5bb0b234\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7521995c elementor-widget elementor-widget-image\" data-id=\"7521995c\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"572\" src=\"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1024x732.jpg\" class=\"attachment-large size-large wp-image-16102\" alt=\"\" srcset=\"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1024x732.jpg 1024w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-300x214.jpg 300w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-768x549.jpg 768w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology-1536x1098.jpg 1536w, https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2025\/05\/MedicalPoint-International-Hospital-Prof.-Serkan-Ozakbas-Neurology.jpg 1652w\" sizes=\"(max-width: 800px) 100vw, 800px\" title=\"\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5f0e7727 e-con-full e-flex e-con e-child\" data-id=\"5f0e7727\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-36508bae elementor-widget elementor-widget-heading\" data-id=\"36508bae\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">&#1575;&#1604;&#1576;&#1585;&#1608;&#1601;&#1610;&#1587;&#1608;&#1585; &#1587;&#1585;&#1603;&#1575;&#1606; &#1571;&#1608;&#1586;&#1575;&#1603;&#1576;&#1575;&#1588;\n\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-762b35a6 elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"762b35a6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<i style=\"color:#ffffff\" class=\"fas fa-map-marker-alt\"><\/i> <span>&#1605;&#1587;&#1578;&#1588;&#1601;&#1609; &#1605;&#1610;&#1583;&#1610;&#1603;&#1575;&#1604; &#1576;&#1608;&#1610;&#1606;&#1578; &#1573;&#1586;&#1605;&#1610;&#1585;<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5fcfe0e2 elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"5fcfe0e2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<span>&#1591;&#1576; &#1575;&#1604;&#1571;&#1593;&#1589;&#1575;&#1576;<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-da0541a e-con-full e-flex e-con e-child\" data-id=\"da0541a\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-2ff01d4d e-con-full e-flex e-con e-child\" data-id=\"2ff01d4d\" data-element_type=\"container\" data-settings='{\"background_background\":\"classic\"}'>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e5c3d23 elementor-widget elementor-widget-heading\" data-id=\"4e5c3d23\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">&#1591;&#1604;&#1576; &#1605;&#1593;&#1575;&#1608;&#1583;&#1577; &#1575;&#1604;&#1575;&#1578;&#1589;&#1575;&#1604;<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7627fcaa ekit_wpForms_container-form-button-full-width elementor-widget-mobile__width-initial elementor-widget elementor-widget-elementskit-wp-forms\" data-id=\"7627fcaa\" data-element_type=\"widget\" data-widget_type=\"elementskit-wp-forms.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con ekit_wpForms_container\"><div class=\"wpforms-container wpforms-container-full wpforms-render-modern\" id=\"wpforms-2447\"><form id=\"wpforms-form-2447\" class=\"wpforms-validate wpforms-form wpforms-ajax-form\" data-formid=\"2447\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/ar\/wp-json\/wp\/v2\/pages\/16099\" data-token=\"4a0dc6b5490a1afb3ee3abfe16bfaa98\" data-token-time=\"1780592684\"><noscript class=\"wpforms-error-noscript\">&#1610;&#1585;&#1580;&#1609; &#1578;&#1601;&#1593;&#1610;&#1604; JavaScript &#1601;&#1610; &#1605;&#1578;&#1589;&#1601;&#1581;&#1603; &#1604;&#1573;&#1603;&#1605;&#1575;&#1604; &#1607;&#1584;&#1575; &#1575;&#1604;&#1606;&#1605;&#1608;&#1584;&#1580;.<\/noscript><div class=\"wpforms-hidden\" id=\"wpforms-error-noscript\">&#1610;&#1585;&#1580;&#1609; &#1578;&#1601;&#1593;&#1610;&#1604; JavaScript &#1601;&#1610; &#1605;&#1578;&#1589;&#1601;&#1581;&#1603; &#1604;&#1573;&#1603;&#1605;&#1575;&#1604; &#1607;&#1584;&#1575; &#1575;&#1604;&#1606;&#1605;&#1608;&#1584;&#1580;.<\/div><div class=\"wpforms-field-container\"><div id=\"wpforms-2447-field_1-container\" class=\"wpforms-field wpforms-field-name\" data-field-id=\"1\"><fieldset><legend class=\"wpforms-field-label wpforms-label-hide\" aria-hidden=\"false\">&#1575;&#1604;&#1575;&#1587;&#1605; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/legend><div class=\"wpforms-field-row wpforms-field-large\"><div class=\"wpforms-field-row-block wpforms-first wpforms-one-half\"><input type=\"text\" id=\"wpforms-2447-field_1\" class=\"wpforms-field-name-first wpforms-field-required\" name=\"wpforms[fields][1][first]\" placeholder=\"&#1575;&#1604;&#1575;&#1587;&#1605;\" aria-errormessage=\"wpforms-2447-field_1-error\" required><label for=\"wpforms-2447-field_1\" class=\"wpforms-field-sublabel after wpforms-sublabel-hide\">&#1571;&#1608;&#1604;&#1575;&#1611;<\/label><\/div><div class=\"wpforms-field-row-block wpforms-one-half\"><input type=\"text\" id=\"wpforms-2447-field_1-last\" class=\"wpforms-field-name-last wpforms-field-required\" name=\"wpforms[fields][1][last]\" placeholder=\"&#1575;&#1604;&#1575;&#1587;&#1605; &#1575;&#1604;&#1593;&#1575;&#1574;&#1604;&#1610;\" aria-errormessage=\"wpforms-2447-field_1-last-error\" required><label for=\"wpforms-2447-field_1-last\" class=\"wpforms-field-sublabel after wpforms-sublabel-hide\">&#1575;&#1604;&#1571;&#1582;&#1610;&#1585;<\/label><\/div><\/div><\/fieldset><\/div><div id=\"wpforms-2447-field_2-container\" class=\"wpforms-field wpforms-field-phone\" data-field-id=\"2\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_2\" aria-hidden=\"false\">&#1575;&#1604;&#1607;&#1575;&#1578;&#1601; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"tel\" id=\"wpforms-2447-field_2\" class=\"wpforms-field-large wpforms-field-required wpforms-smart-phone-field\" data-rule-smart-phone-field=\"true\" name=\"wpforms[fields][2]\" placeholder=\"&#1575;&#1604;&#1607;&#1575;&#1578;&#1601;\" aria-label=\"&#1575;&#1604;&#1607;&#1575;&#1578;&#1601;\" aria-errormessage=\"wpforms-2447-field_2-error\" required><\/div><div id=\"wpforms-2447-field_4-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"4\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_4\" aria-hidden=\"false\">&#1575;&#1604;&#1576;&#1585;&#1610;&#1583; &#1575;&#1604;&#1573;&#1604;&#1603;&#1578;&#1585;&#1608;&#1606;&#1610; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"email\" id=\"wpforms-2447-field_4\" class=\"wpforms-field-large wpforms-field-required\" name=\"wpforms[fields][4]\" placeholder=\"&#1575;&#1604;&#1576;&#1585;&#1610;&#1583; &#1575;&#1604;&#1573;&#1604;&#1603;&#1578;&#1585;&#1608;&#1606;&#1610;\" spellcheck=\"false\" aria-errormessage=\"wpforms-2447-field_4-error\" required><\/div><div id=\"wpforms-2447-field_7-container\" class=\"wpforms-field wpforms-field-select wpforms-field-select-style-modern\" data-field-id=\"7\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-2447-field_7\" aria-hidden=\"false\">&#1575;&#1604;&#1576;&#1604;&#1583; <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><select id=\"wpforms-2447-field_7\" class=\"wpforms-field-large wpforms-field-required choicesjs-select\" data-size-class=\"wpforms-field-row wpforms-field-large\" data-search-enabled=\"1\" name=\"wpforms[fields][7]\" required=\"required\"><option value=\"\" class=\"placeholder\" disabled selected>&#1575;&#1604;&#1576;&#1604;&#1583;<\/option><option value=\"&#1571;&#1601;&#1594;&#1575;&#1606;&#1587;&#1578;&#1575;&#1606;\">&#1571;&#1601;&#1594;&#1575;&#1606;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1571;&#1604;&#1576;&#1575;&#1606;&#1610;&#1575;\">&#1571;&#1604;&#1576;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1575;&#1604;&#1580;&#1586;&#1575;&#1574;&#1585;\">&#1575;&#1604;&#1580;&#1586;&#1575;&#1574;&#1585;<\/option><option value=\"&#1571;&#1606;&#1583;&#1608;&#1585;&#1575;\">&#1571;&#1606;&#1583;&#1608;&#1585;&#1575;<\/option><option value=\"&#1571;&#1606;&#1594;&#1608;&#1604;&#1575;\">&#1571;&#1606;&#1594;&#1608;&#1604;&#1575;<\/option><option value=\"&#1571;&#1606;&#1578;&#1610;&#1594;&#1608;&#1575; &#1608;&#1576;&#1575;&#1585;&#1576;&#1608;&#1583;&#1575;\">&#1571;&#1606;&#1578;&#1610;&#1594;&#1608;&#1575; &#1608;&#1576;&#1575;&#1585;&#1576;&#1608;&#1583;&#1575;<\/option><option value=\"&#1575;&#1604;&#1571;&#1585;&#1580;&#1606;&#1578;&#1610;&#1606;\">&#1575;&#1604;&#1571;&#1585;&#1580;&#1606;&#1578;&#1610;&#1606;<\/option><option value=\"&#1571;&#1585;&#1605;&#1610;&#1606;&#1610;&#1575;\">&#1571;&#1585;&#1605;&#1610;&#1606;&#1610;&#1575;<\/option><option value=\"&#1575;&#1587;&#1578;&#1585;&#1575;&#1604;&#1610;&#1575;\">&#1575;&#1587;&#1578;&#1585;&#1575;&#1604;&#1610;&#1575;<\/option><option value=\"&#1575;&#1604;&#1606;&#1605;&#1587;&#1575;\">&#1575;&#1604;&#1606;&#1605;&#1587;&#1575;<\/option><option value=\"&#1571;&#1584;&#1585;&#1576;&#1610;&#1580;&#1575;&#1606;\">&#1571;&#1584;&#1585;&#1576;&#1610;&#1580;&#1575;&#1606;<\/option><option value=\"&#1580;&#1586;&#1585; &#1575;&#1604;&#1576;&#1607;&#1575;&#1605;&#1575;\">&#1580;&#1586;&#1585; &#1575;&#1604;&#1576;&#1607;&#1575;&#1605;&#1575;<\/option><option value=\"&#1575;&#1604;&#1576;&#1581;&#1585;&#1610;&#1606;\">&#1575;&#1604;&#1576;&#1581;&#1585;&#1610;&#1606;<\/option><option value=\"&#1576;&#1606;&#1594;&#1604;&#1575;&#1583;&#1610;&#1588;\">&#1576;&#1606;&#1594;&#1604;&#1575;&#1583;&#1610;&#1588;<\/option><option value=\"&#1576;&#1585;&#1576;&#1575;&#1583;&#1608;&#1587;\">&#1576;&#1585;&#1576;&#1575;&#1583;&#1608;&#1587;<\/option><option value=\"&#1576;&#1610;&#1604;&#1575;&#1585;&#1608;&#1587;&#1610;&#1575;\">&#1576;&#1610;&#1604;&#1575;&#1585;&#1608;&#1587;&#1610;&#1575;<\/option><option value=\"&#1576;&#1604;&#1580;&#1610;&#1603;&#1575;\">&#1576;&#1604;&#1580;&#1610;&#1603;&#1575;<\/option><option value=\"&#1576;&#1604;&#1610;&#1586;\">&#1576;&#1604;&#1610;&#1586;<\/option><option value=\"&#1576;&#1606;&#1610;&#1606;\">&#1576;&#1606;&#1610;&#1606;<\/option><option value=\"&#1576;&#1608;&#1578;&#1575;&#1606;\">&#1576;&#1608;&#1578;&#1575;&#1606;<\/option><option value=\"&#1576;&#1608;&#1604;&#1610;&#1601;&#1610;&#1575;\">&#1576;&#1608;&#1604;&#1610;&#1601;&#1610;&#1575;<\/option><option value=\"&#1575;&#1604;&#1576;&#1608;&#1587;&#1606;&#1577; &#1608;&#1575;&#1604;&#1607;&#1585;&#1587;&#1603;\">&#1575;&#1604;&#1576;&#1608;&#1587;&#1606;&#1577; &#1608;&#1575;&#1604;&#1607;&#1585;&#1587;&#1603;<\/option><option value=\"&#1576;&#1608;&#1578;&#1587;&#1608;&#1575;&#1606;&#1575;\">&#1576;&#1608;&#1578;&#1587;&#1608;&#1575;&#1606;&#1575;<\/option><option value=\"&#1575;&#1604;&#1576;&#1585;&#1575;&#1586;&#1610;&#1604;\">&#1575;&#1604;&#1576;&#1585;&#1575;&#1586;&#1610;&#1604;<\/option><option value=\"&#1576;&#1585;&#1608;&#1606;&#1575;&#1610;\">&#1576;&#1585;&#1608;&#1606;&#1575;&#1610;<\/option><option value=\"&#1576;&#1604;&#1594;&#1575;&#1585;&#1610;&#1575;\">&#1576;&#1604;&#1594;&#1575;&#1585;&#1610;&#1575;<\/option><option value=\"&#1576;&#1608;&#1585;&#1603;&#1610;&#1606;&#1575; &#1601;&#1575;&#1587;&#1608;\">&#1576;&#1608;&#1585;&#1603;&#1610;&#1606;&#1575; &#1601;&#1575;&#1587;&#1608;<\/option><option value=\"&#1576;&#1608;&#1585;&#1608;&#1606;&#1583;&#1610;\">&#1576;&#1608;&#1585;&#1608;&#1606;&#1583;&#1610;<\/option><option value=\"&#1603;&#1575;&#1576;&#1608; &#1601;&#1610;&#1585;&#1583;&#1610;\">&#1603;&#1575;&#1576;&#1608; &#1601;&#1610;&#1585;&#1583;&#1610;<\/option><option value=\"&#1603;&#1605;&#1576;&#1608;&#1583;&#1610;&#1575;\">&#1603;&#1605;&#1576;&#1608;&#1583;&#1610;&#1575;<\/option><option value=\"&#1575;&#1604;&#1603;&#1575;&#1605;&#1610;&#1585;&#1608;&#1606;\">&#1575;&#1604;&#1603;&#1575;&#1605;&#1610;&#1585;&#1608;&#1606;<\/option><option value=\"&#1603;&#1606;&#1583;&#1575;\">&#1603;&#1606;&#1583;&#1575;<\/option><option value=\"&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1571;&#1601;&#1585;&#1610;&#1602;&#1610;&#1575; &#1575;&#1604;&#1608;&#1587;&#1591;&#1609;\">&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1571;&#1601;&#1585;&#1610;&#1602;&#1610;&#1575; &#1575;&#1604;&#1608;&#1587;&#1591;&#1609;<\/option><option value=\"&#1578;&#1588;&#1575;&#1583;\">&#1578;&#1588;&#1575;&#1583;<\/option><option value=\"&#1588;&#1610;&#1604;&#1610;\">&#1588;&#1610;&#1604;&#1610;<\/option><option value=\"&#1575;&#1604;&#1589;&#1610;&#1606;\">&#1575;&#1604;&#1589;&#1610;&#1606;<\/option><option value=\"&#1603;&#1608;&#1604;&#1608;&#1605;&#1576;&#1610;&#1575;\">&#1603;&#1608;&#1604;&#1608;&#1605;&#1576;&#1610;&#1575;<\/option><option value=\"&#1580;&#1586;&#1585; &#1575;&#1604;&#1602;&#1605;&#1585;\">&#1580;&#1586;&#1585; &#1575;&#1604;&#1602;&#1605;&#1585;<\/option><option value=\"&#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608;&#1548; &#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608; &#1575;&#1604;&#1583;&#1610;&#1605;&#1602;&#1585;&#1575;&#1591;&#1610;&#1577;\">&#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608;&#1548; &#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608; &#1575;&#1604;&#1583;&#1610;&#1605;&#1602;&#1585;&#1575;&#1591;&#1610;&#1577;<\/option><option value=\"&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608; &#1575;&#1604;&#1583;&#1610;&#1605;&#1602;&#1585;&#1575;&#1591;&#1610;&#1577;\">&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1603;&#1608;&#1606;&#1594;&#1608; &#1575;&#1604;&#1583;&#1610;&#1605;&#1602;&#1585;&#1575;&#1591;&#1610;&#1577;<\/option><option value=\"&#1603;&#1608;&#1587;&#1578;&#1575;&#1585;&#1610;&#1603;&#1575;\">&#1603;&#1608;&#1587;&#1578;&#1575;&#1585;&#1610;&#1603;&#1575;<\/option><option value=\"&#1603;&#1608;&#1578; &#1583;&#1610;&#1601;&#1608;&#1575;&#1585;\">&#1603;&#1608;&#1578; &#1583;&#1610;&#1601;&#1608;&#1575;&#1585;<\/option><option value=\"&#1603;&#1585;&#1608;&#1575;&#1578;&#1610;&#1575;\">&#1603;&#1585;&#1608;&#1575;&#1578;&#1610;&#1575;<\/option><option value=\"&#1603;&#1608;&#1576;&#1575;\">&#1603;&#1608;&#1576;&#1575;<\/option><option value=\"&#1602;&#1576;&#1585;&#1589;\">&#1602;&#1576;&#1585;&#1589;<\/option><option value=\"&#1575;&#1604;&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1578;&#1588;&#1610;&#1603;&#1610;&#1577;\">&#1575;&#1604;&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1578;&#1588;&#1610;&#1603;&#1610;&#1577;<\/option><option value=\"&#1575;&#1604;&#1583;&#1606;&#1605;&#1575;&#1585;&#1603;\">&#1575;&#1604;&#1583;&#1606;&#1605;&#1575;&#1585;&#1603;<\/option><option value=\"&#1580;&#1610;&#1576;&#1608;&#1578;&#1610;\">&#1580;&#1610;&#1576;&#1608;&#1578;&#1610;<\/option><option value=\"&#1583;&#1608;&#1605;&#1610;&#1606;&#1610;&#1603;&#1575;\">&#1583;&#1608;&#1605;&#1610;&#1606;&#1610;&#1603;&#1575;<\/option><option value=\"&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1583;&#1608;&#1605;&#1610;&#1606;&#1610;&#1603;&#1575;&#1606;\">&#1580;&#1605;&#1607;&#1608;&#1585;&#1610;&#1577; &#1575;&#1604;&#1583;&#1608;&#1605;&#1610;&#1606;&#1610;&#1603;&#1575;&#1606;<\/option><option value=\"&#1578;&#1610;&#1605;&#1608;&#1585; &#1575;&#1604;&#1588;&#1585;&#1602;&#1610;&#1577; (&#1578;&#1610;&#1605;&#1608;&#1585; &#1575;&#1604;&#1588;&#1585;&#1602;&#1610;&#1577;)\">&#1578;&#1610;&#1605;&#1608;&#1585; &#1575;&#1604;&#1588;&#1585;&#1602;&#1610;&#1577; (&#1578;&#1610;&#1605;&#1608;&#1585; &#1575;&#1604;&#1588;&#1585;&#1602;&#1610;&#1577;)<\/option><option value=\"&#1575;&#1604;&#1573;&#1603;&#1608;&#1575;&#1583;&#1608;&#1585;\">&#1575;&#1604;&#1573;&#1603;&#1608;&#1575;&#1583;&#1608;&#1585;<\/option><option value=\"&#1605;&#1589;&#1585;\">&#1605;&#1589;&#1585;<\/option><option value=\"&#1575;&#1604;&#1587;&#1604;&#1601;&#1575;&#1583;&#1608;&#1585;\">&#1575;&#1604;&#1587;&#1604;&#1601;&#1575;&#1583;&#1608;&#1585;<\/option><option value=\"&#1594;&#1610;&#1606;&#1610;&#1575; &#1575;&#1604;&#1575;&#1587;&#1578;&#1608;&#1575;&#1574;&#1610;&#1577;\">&#1594;&#1610;&#1606;&#1610;&#1575; &#1575;&#1604;&#1575;&#1587;&#1578;&#1608;&#1575;&#1574;&#1610;&#1577;<\/option><option value=\"&#1573;&#1585;&#1610;&#1578;&#1585;&#1610;&#1575;\">&#1573;&#1585;&#1610;&#1578;&#1585;&#1610;&#1575;<\/option><option value=\"&#1573;&#1587;&#1578;&#1608;&#1606;&#1610;&#1575;\">&#1573;&#1587;&#1578;&#1608;&#1606;&#1610;&#1575;<\/option><option value=\"&#1573;&#1610;&#1587;&#1608;&#1575;&#1578;&#1610;&#1606;&#1610;\">&#1573;&#1610;&#1587;&#1608;&#1575;&#1578;&#1610;&#1606;&#1610;<\/option><option value=\"&#1573;&#1579;&#1610;&#1608;&#1576;&#1610;&#1575;\">&#1573;&#1579;&#1610;&#1608;&#1576;&#1610;&#1575;<\/option><option value=\"&#1601;&#1610;&#1580;&#1610;\">&#1601;&#1610;&#1580;&#1610;<\/option><option value=\"&#1601;&#1606;&#1604;&#1606;&#1583;&#1575;\">&#1601;&#1606;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1601;&#1585;&#1606;&#1587;&#1575;\">&#1601;&#1585;&#1606;&#1587;&#1575;<\/option><option value=\"&#1594;&#1575;&#1606;&#1575;\">&#1594;&#1575;&#1606;&#1575;<\/option><option value=\"&#1575;&#1604;&#1610;&#1608;&#1606;&#1575;&#1606;\">&#1575;&#1604;&#1610;&#1608;&#1606;&#1575;&#1606;<\/option><option value=\"&#1594;&#1585;&#1610;&#1606;&#1575;&#1583;&#1575;\">&#1594;&#1585;&#1610;&#1606;&#1575;&#1583;&#1575;<\/option><option value=\"&#1594;&#1608;&#1575;&#1578;&#1610;&#1605;&#1575;&#1604;&#1575;\">&#1594;&#1608;&#1575;&#1578;&#1610;&#1605;&#1575;&#1604;&#1575;<\/option><option value=\"&#1594;&#1610;&#1606;&#1610;&#1575;\">&#1594;&#1610;&#1606;&#1610;&#1575;<\/option><option value=\"&#1594;&#1610;&#1606;&#1610;&#1575; &#1576;&#1610;&#1587;&#1575;&#1608;\">&#1594;&#1610;&#1606;&#1610;&#1575; &#1576;&#1610;&#1587;&#1575;&#1608;<\/option><option value=\"&#1594;&#1610;&#1575;&#1606;&#1575;\">&#1594;&#1610;&#1575;&#1606;&#1575;<\/option><option value=\"&#1607;&#1575;&#1610;&#1578;&#1610;\">&#1607;&#1575;&#1610;&#1578;&#1610;<\/option><option value=\"&#1607;&#1606;&#1583;&#1608;&#1585;&#1575;&#1587;\">&#1607;&#1606;&#1583;&#1608;&#1585;&#1575;&#1587;<\/option><option value=\"&#1607;&#1606;&#1594;&#1575;&#1585;&#1610;&#1575;\">&#1607;&#1606;&#1594;&#1575;&#1585;&#1610;&#1575;<\/option><option value=\"&#1571;&#1610;&#1587;&#1604;&#1606;&#1583;&#1575;\">&#1571;&#1610;&#1587;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1575;&#1604;&#1607;&#1606;&#1583;\">&#1575;&#1604;&#1607;&#1606;&#1583;<\/option><option value=\"&#1573;&#1606;&#1583;&#1608;&#1606;&#1610;&#1587;&#1610;&#1575;\">&#1573;&#1606;&#1583;&#1608;&#1606;&#1610;&#1587;&#1610;&#1575;<\/option><option value=\"&#1573;&#1610;&#1585;&#1575;&#1606;\">&#1573;&#1610;&#1585;&#1575;&#1606;<\/option><option value=\"&#1575;&#1604;&#1593;&#1585;&#1575;&#1602;\">&#1575;&#1604;&#1593;&#1585;&#1575;&#1602;<\/option><option value=\"&#1571;&#1610;&#1585;&#1604;&#1606;&#1583;&#1575;\">&#1571;&#1610;&#1585;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1573;&#1587;&#1585;&#1575;&#1574;&#1610;&#1604;\">&#1573;&#1587;&#1585;&#1575;&#1574;&#1610;&#1604;<\/option><option value=\"&#1575;&#1610;&#1591;&#1575;&#1604;&#1610;&#1575;\">&#1575;&#1610;&#1591;&#1575;&#1604;&#1610;&#1575;<\/option><option value=\"&#1580;&#1575;&#1605;&#1575;&#1610;&#1603;&#1575;\">&#1580;&#1575;&#1605;&#1575;&#1610;&#1603;&#1575;<\/option><option value=\"&#1575;&#1604;&#1610;&#1575;&#1576;&#1575;&#1606;\">&#1575;&#1604;&#1610;&#1575;&#1576;&#1575;&#1606;<\/option><option value=\"&#1603;&#1575;&#1586;&#1575;&#1582;&#1587;&#1578;&#1575;&#1606;\">&#1603;&#1575;&#1586;&#1575;&#1582;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1603;&#1610;&#1606;&#1610;&#1575;\">&#1603;&#1610;&#1606;&#1610;&#1575;<\/option><option value=\"&#1603;&#1610;&#1585;&#1610;&#1576;&#1575;&#1578;&#1610;\">&#1603;&#1610;&#1585;&#1610;&#1576;&#1575;&#1578;&#1610;<\/option><option value=\"&#1603;&#1608;&#1585;&#1610;&#1575;&#1548; &#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1588;&#1605;&#1575;&#1604;&#1610;&#1577;\">&#1603;&#1608;&#1585;&#1610;&#1575;&#1548; &#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1588;&#1605;&#1575;&#1604;&#1610;&#1577;<\/option><option value=\"&#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1580;&#1606;&#1608;&#1576;&#1610;&#1577;&#1548; &#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1580;&#1606;&#1608;&#1576;&#1610;&#1577;\">&#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1580;&#1606;&#1608;&#1576;&#1610;&#1577;&#1548; &#1603;&#1608;&#1585;&#1610;&#1575; &#1575;&#1604;&#1580;&#1606;&#1608;&#1576;&#1610;&#1577;<\/option><option value=\"&#1603;&#1608;&#1587;&#1608;&#1601;&#1608;\">&#1603;&#1608;&#1587;&#1608;&#1601;&#1608;<\/option><option value=\"&#1575;&#1604;&#1603;&#1608;&#1610;&#1578;\">&#1575;&#1604;&#1603;&#1608;&#1610;&#1578;<\/option><option value=\"&#1602;&#1610;&#1585;&#1594;&#1610;&#1586;&#1587;&#1578;&#1575;&#1606;\">&#1602;&#1610;&#1585;&#1594;&#1610;&#1586;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1604;&#1575;&#1608;&#1587;\">&#1604;&#1575;&#1608;&#1587;<\/option><option value=\"&#1604;&#1575;&#1578;&#1601;&#1610;&#1575;\">&#1604;&#1575;&#1578;&#1601;&#1610;&#1575;<\/option><option value=\"&#1604;&#1576;&#1606;&#1575;&#1606;\">&#1604;&#1576;&#1606;&#1575;&#1606;<\/option><option value=\"&#1604;&#1610;&#1587;&#1608;&#1578;&#1608;\">&#1604;&#1610;&#1587;&#1608;&#1578;&#1608;<\/option><option value=\"&#1604;&#1610;&#1582;&#1578;&#1606;&#1588;&#1578;&#1575;&#1610;&#1606;\">&#1604;&#1610;&#1582;&#1578;&#1606;&#1588;&#1578;&#1575;&#1610;&#1606;<\/option><option value=\"&#1604;&#1610;&#1578;&#1608;&#1575;&#1606;&#1610;&#1575;\">&#1604;&#1610;&#1578;&#1608;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1604;&#1608;&#1603;&#1587;&#1605;&#1576;&#1608;&#1585;&#1594;\">&#1604;&#1608;&#1603;&#1587;&#1605;&#1576;&#1608;&#1585;&#1594;<\/option><option value=\"&#1605;&#1583;&#1594;&#1588;&#1602;&#1585;\">&#1605;&#1583;&#1594;&#1588;&#1602;&#1585;<\/option><option value=\"&#1605;&#1604;&#1575;&#1608;&#1610;\">&#1605;&#1604;&#1575;&#1608;&#1610;<\/option><option value=\"&#1605;&#1575;&#1604;&#1610;&#1586;&#1610;&#1575;\">&#1605;&#1575;&#1604;&#1610;&#1586;&#1610;&#1575;<\/option><option value=\"&#1580;&#1586;&#1585; &#1575;&#1604;&#1605;&#1575;&#1604;&#1583;&#1610;&#1601;\">&#1580;&#1586;&#1585; &#1575;&#1604;&#1605;&#1575;&#1604;&#1583;&#1610;&#1601;<\/option><option value=\"&#1605;&#1575;&#1604;&#1610;\">&#1605;&#1575;&#1604;&#1610;<\/option><option value=\"&#1605;&#1575;&#1604;&#1591;&#1575;\">&#1605;&#1575;&#1604;&#1591;&#1575;<\/option><option value=\"&#1605;&#1608;&#1585;&#1610;&#1588;&#1610;&#1608;&#1587;\">&#1605;&#1608;&#1585;&#1610;&#1588;&#1610;&#1608;&#1587;<\/option><option value=\"&#1575;&#1604;&#1605;&#1603;&#1587;&#1610;&#1603;\">&#1575;&#1604;&#1605;&#1603;&#1587;&#1610;&#1603;<\/option><option value=\"&#1605;&#1610;&#1603;&#1585;&#1608;&#1606;&#1610;&#1586;&#1610;&#1575;&#1548; &#1608;&#1604;&#1575;&#1610;&#1575;&#1578; &#1605;&#1610;&#1603;&#1585;&#1608;&#1606;&#1610;&#1586;&#1610;&#1575; &#1575;&#1604;&#1605;&#1608;&#1581;&#1583;&#1577;\">&#1605;&#1610;&#1603;&#1585;&#1608;&#1606;&#1610;&#1586;&#1610;&#1575;&#1548; &#1608;&#1604;&#1575;&#1610;&#1575;&#1578; &#1605;&#1610;&#1603;&#1585;&#1608;&#1606;&#1610;&#1586;&#1610;&#1575; &#1575;&#1604;&#1605;&#1608;&#1581;&#1583;&#1577;<\/option><option value=\"&#1605;&#1608;&#1604;&#1583;&#1608;&#1601;&#1575;\">&#1605;&#1608;&#1604;&#1583;&#1608;&#1601;&#1575;<\/option><option value=\"&#1605;&#1608;&#1606;&#1575;&#1603;&#1608;\">&#1605;&#1608;&#1606;&#1575;&#1603;&#1608;<\/option><option value=\"&#1605;&#1606;&#1594;&#1608;&#1604;&#1610;&#1575;\">&#1605;&#1606;&#1594;&#1608;&#1604;&#1610;&#1575;<\/option><option value=\"&#1605;&#1608;&#1606;&#1578;&#1610;&#1606;&#1610;&#1594;&#1585;&#1608;\">&#1605;&#1608;&#1606;&#1578;&#1610;&#1606;&#1610;&#1594;&#1585;&#1608;<\/option><option value=\"&#1575;&#1604;&#1605;&#1594;&#1585;&#1576;\">&#1575;&#1604;&#1605;&#1594;&#1585;&#1576;<\/option><option value=\"&#1605;&#1608;&#1586;&#1605;&#1576;&#1610;&#1602;\">&#1605;&#1608;&#1586;&#1605;&#1576;&#1610;&#1602;<\/option><option value=\"&#1605;&#1610;&#1575;&#1606;&#1605;&#1575;&#1585; (&#1576;&#1608;&#1585;&#1605;&#1575;)\">&#1605;&#1610;&#1575;&#1606;&#1605;&#1575;&#1585; (&#1576;&#1608;&#1585;&#1605;&#1575;)<\/option><option value=\"&#1606;&#1575;&#1605;&#1610;&#1576;&#1610;&#1575;\">&#1606;&#1575;&#1605;&#1610;&#1576;&#1610;&#1575;<\/option><option value=\"&#1606;&#1575;&#1608;&#1585;&#1608;\">&#1606;&#1575;&#1608;&#1585;&#1608;<\/option><option value=\"&#1606;&#1610;&#1576;&#1575;&#1604;\">&#1606;&#1610;&#1576;&#1575;&#1604;<\/option><option value=\"&#1607;&#1608;&#1604;&#1606;&#1583;&#1575;\">&#1607;&#1608;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1606;&#1610;&#1608;&#1586;&#1610;&#1604;&#1606;&#1583;&#1575;\">&#1606;&#1610;&#1608;&#1586;&#1610;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1606;&#1610;&#1603;&#1575;&#1585;&#1575;&#1594;&#1608;&#1575;\">&#1606;&#1610;&#1603;&#1575;&#1585;&#1575;&#1594;&#1608;&#1575;<\/option><option value=\"&#1575;&#1604;&#1606;&#1610;&#1580;&#1585;\">&#1575;&#1604;&#1606;&#1610;&#1580;&#1585;<\/option><option value=\"&#1606;&#1610;&#1580;&#1610;&#1585;&#1610;&#1575;\">&#1606;&#1610;&#1580;&#1610;&#1585;&#1610;&#1575;<\/option><option value=\"&#1605;&#1602;&#1583;&#1608;&#1606;&#1610;&#1575; &#1575;&#1604;&#1588;&#1605;&#1575;&#1604;&#1610;&#1577;\">&#1605;&#1602;&#1583;&#1608;&#1606;&#1610;&#1575; &#1575;&#1604;&#1588;&#1605;&#1575;&#1604;&#1610;&#1577;<\/option><option value=\"&#1575;&#1604;&#1606;&#1585;&#1608;&#1610;&#1580;\">&#1575;&#1604;&#1606;&#1585;&#1608;&#1610;&#1580;<\/option><option value=\"&#1587;&#1604;&#1591;&#1606;&#1577; &#1593;&#1605;&#1575;&#1606;\">&#1587;&#1604;&#1591;&#1606;&#1577; &#1593;&#1605;&#1575;&#1606;<\/option><option value=\"&#1576;&#1575;&#1603;&#1587;&#1578;&#1575;&#1606;\">&#1576;&#1575;&#1603;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1576;&#1575;&#1604;&#1575;&#1608;\">&#1576;&#1575;&#1604;&#1575;&#1608;<\/option><option value=\"&#1576;&#1606;&#1605;&#1575;\">&#1576;&#1606;&#1605;&#1575;<\/option><option value=\"&#1576;&#1575;&#1576;&#1608;&#1575; &#1594;&#1610;&#1606;&#1610;&#1575; &#1575;&#1604;&#1580;&#1583;&#1610;&#1583;&#1577;\">&#1576;&#1575;&#1576;&#1608;&#1575; &#1594;&#1610;&#1606;&#1610;&#1575; &#1575;&#1604;&#1580;&#1583;&#1610;&#1583;&#1577;<\/option><option value=\"&#1576;&#1575;&#1585;&#1575;&#1594;&#1608;&#1575;&#1610;\">&#1576;&#1575;&#1585;&#1575;&#1594;&#1608;&#1575;&#1610;<\/option><option value=\"&#1576;&#1610;&#1585;&#1608;\">&#1576;&#1610;&#1585;&#1608;<\/option><option value=\"&#1575;&#1604;&#1601;&#1604;&#1576;&#1610;&#1606;\">&#1575;&#1604;&#1601;&#1604;&#1576;&#1610;&#1606;<\/option><option value=\"&#1576;&#1608;&#1604;&#1606;&#1583;&#1575;\">&#1576;&#1608;&#1604;&#1606;&#1583;&#1575;<\/option><option value=\"&#1575;&#1604;&#1576;&#1585;&#1578;&#1594;&#1575;&#1604;\">&#1575;&#1604;&#1576;&#1585;&#1578;&#1594;&#1575;&#1604;<\/option><option value=\"&#1602;&#1591;&#1585;\">&#1602;&#1591;&#1585;<\/option><option value=\"&#1585;&#1608;&#1605;&#1575;&#1606;&#1610;&#1575;\">&#1585;&#1608;&#1605;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1585;&#1608;&#1587;&#1610;&#1575;\">&#1585;&#1608;&#1587;&#1610;&#1575;<\/option><option value=\"&#1585;&#1608;&#1575;&#1606;&#1583;&#1575;\">&#1585;&#1608;&#1575;&#1606;&#1583;&#1575;<\/option><option value=\"&#1587;&#1575;&#1606;&#1578; &#1603;&#1610;&#1578;&#1587; &#1608;&#1606;&#1610;&#1601;&#1610;&#1587;\">&#1587;&#1575;&#1606;&#1578; &#1603;&#1610;&#1578;&#1587; &#1608;&#1606;&#1610;&#1601;&#1610;&#1587;<\/option><option value=\"&#1587;&#1575;&#1606;&#1578; &#1604;&#1608;&#1587;&#1610;&#1575;\">&#1587;&#1575;&#1606;&#1578; &#1604;&#1608;&#1587;&#1610;&#1575;<\/option><option value=\"&#1587;&#1575;&#1606;&#1578; &#1601;&#1606;&#1587;&#1606;&#1578; &#1608;&#1580;&#1586;&#1585; &#1594;&#1585;&#1610;&#1606;&#1575;&#1583;&#1610;&#1606;\">&#1587;&#1575;&#1606;&#1578; &#1601;&#1606;&#1587;&#1606;&#1578; &#1608;&#1580;&#1586;&#1585; &#1594;&#1585;&#1610;&#1606;&#1575;&#1583;&#1610;&#1606;<\/option><option value=\"&#1587;&#1575;&#1605;&#1608;&#1575;\">&#1587;&#1575;&#1605;&#1608;&#1575;<\/option><option value=\"&#1587;&#1575;&#1606; &#1605;&#1575;&#1585;&#1610;&#1606;&#1608;\">&#1587;&#1575;&#1606; &#1605;&#1575;&#1585;&#1610;&#1606;&#1608;<\/option><option value=\"&#1587;&#1575;&#1608; &#1578;&#1608;&#1605;&#1610; &#1608;&#1576;&#1585;&#1610;&#1606;&#1587;&#1610;&#1576;&#1610;\">&#1587;&#1575;&#1608; &#1578;&#1608;&#1605;&#1610; &#1608;&#1576;&#1585;&#1610;&#1606;&#1587;&#1610;&#1576;&#1610;<\/option><option value=\"&#1575;&#1604;&#1605;&#1605;&#1604;&#1603;&#1577; &#1575;&#1604;&#1593;&#1585;&#1576;&#1610;&#1577; &#1575;&#1604;&#1587;&#1593;&#1608;&#1583;&#1610;&#1577;\">&#1575;&#1604;&#1605;&#1605;&#1604;&#1603;&#1577; &#1575;&#1604;&#1593;&#1585;&#1576;&#1610;&#1577; &#1575;&#1604;&#1587;&#1593;&#1608;&#1583;&#1610;&#1577;<\/option><option value=\"&#1575;&#1604;&#1587;&#1606;&#1594;&#1575;&#1604;\">&#1575;&#1604;&#1587;&#1606;&#1594;&#1575;&#1604;<\/option><option value=\"&#1589;&#1585;&#1576;&#1610;&#1575;\">&#1589;&#1585;&#1576;&#1610;&#1575;<\/option><option value=\"&#1587;&#1610;&#1588;&#1610;&#1604;\">&#1587;&#1610;&#1588;&#1610;&#1604;<\/option><option value=\"&#1587;&#1610;&#1585;&#1575;&#1604;&#1610;&#1608;&#1606;\">&#1587;&#1610;&#1585;&#1575;&#1604;&#1610;&#1608;&#1606;<\/option><option value=\"&#1587;&#1606;&#1594;&#1575;&#1601;&#1608;&#1585;&#1577;\">&#1587;&#1606;&#1594;&#1575;&#1601;&#1608;&#1585;&#1577;<\/option><option value=\"&#1587;&#1604;&#1608;&#1601;&#1575;&#1603;&#1610;&#1575;\">&#1587;&#1604;&#1608;&#1601;&#1575;&#1603;&#1610;&#1575;<\/option><option value=\"&#1587;&#1604;&#1608;&#1601;&#1610;&#1606;&#1610;&#1575;\">&#1587;&#1604;&#1608;&#1601;&#1610;&#1606;&#1610;&#1575;<\/option><option value=\"&#1580;&#1586;&#1585; &#1587;&#1604;&#1610;&#1605;&#1575;&#1606;\">&#1580;&#1586;&#1585; &#1587;&#1604;&#1610;&#1605;&#1575;&#1606;<\/option><option value=\"&#1575;&#1604;&#1589;&#1608;&#1605;&#1575;&#1604;\">&#1575;&#1604;&#1589;&#1608;&#1605;&#1575;&#1604;<\/option><option value=\"&#1580;&#1606;&#1608;&#1576; &#1571;&#1601;&#1585;&#1610;&#1602;&#1610;&#1575;\">&#1580;&#1606;&#1608;&#1576; &#1571;&#1601;&#1585;&#1610;&#1602;&#1610;&#1575;<\/option><option value=\"&#1575;&#1587;&#1576;&#1575;&#1606;&#1610;&#1575;\">&#1575;&#1587;&#1576;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1587;&#1585;&#1610;&#1604;&#1575;&#1606;&#1603;&#1575;\">&#1587;&#1585;&#1610;&#1604;&#1575;&#1606;&#1603;&#1575;<\/option><option value=\"&#1575;&#1604;&#1587;&#1608;&#1583;&#1575;&#1606;\">&#1575;&#1604;&#1587;&#1608;&#1583;&#1575;&#1606;<\/option><option value=\"&#1575;&#1604;&#1587;&#1608;&#1583;&#1575;&#1606;&#1548; &#1580;&#1606;&#1608;&#1576;\">&#1575;&#1604;&#1587;&#1608;&#1583;&#1575;&#1606;&#1548; &#1580;&#1606;&#1608;&#1576;<\/option><option value=\"&#1587;&#1608;&#1585;&#1610;&#1606;&#1575;&#1605;\">&#1587;&#1608;&#1585;&#1610;&#1606;&#1575;&#1605;<\/option><option value=\"&#1575;&#1604;&#1587;&#1608;&#1610;&#1583;\">&#1575;&#1604;&#1587;&#1608;&#1610;&#1583;<\/option><option value=\"&#1587;&#1608;&#1610;&#1587;&#1585;&#1575;\">&#1587;&#1608;&#1610;&#1587;&#1585;&#1575;<\/option><option value=\"&#1587;&#1608;&#1585;&#1610;&#1575;\">&#1587;&#1608;&#1585;&#1610;&#1575;<\/option><option value=\"&#1578;&#1575;&#1610;&#1608;&#1575;&#1606;\">&#1578;&#1575;&#1610;&#1608;&#1575;&#1606;<\/option><option value=\"&#1591;&#1575;&#1580;&#1610;&#1603;&#1587;&#1578;&#1575;&#1606;\">&#1591;&#1575;&#1580;&#1610;&#1603;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1578;&#1606;&#1586;&#1575;&#1606;&#1610;&#1575;\">&#1578;&#1606;&#1586;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1578;&#1575;&#1610;&#1604;&#1575;&#1606;&#1583;\">&#1578;&#1575;&#1610;&#1604;&#1575;&#1606;&#1583;<\/option><option value=\"&#1578;&#1608;&#1594;&#1608;\">&#1578;&#1608;&#1594;&#1608;<\/option><option value=\"&#1578;&#1608;&#1606;&#1594;&#1575;\">&#1578;&#1608;&#1606;&#1594;&#1575;<\/option><option value=\"&#1578;&#1585;&#1610;&#1606;&#1610;&#1583;&#1575;&#1583; &#1608;&#1578;&#1608;&#1576;&#1575;&#1594;&#1608;\">&#1578;&#1585;&#1610;&#1606;&#1610;&#1583;&#1575;&#1583; &#1608;&#1578;&#1608;&#1576;&#1575;&#1594;&#1608;<\/option><option value=\"&#1578;&#1608;&#1606;&#1587;\">&#1578;&#1608;&#1606;&#1587;<\/option><option value=\"&#1578;&#1585;&#1603;&#1610;&#1575;\">&#1578;&#1585;&#1603;&#1610;&#1575;<\/option><option value=\"&#1578;&#1585;&#1603;&#1605;&#1575;&#1606;&#1587;&#1578;&#1575;&#1606;\">&#1578;&#1585;&#1603;&#1605;&#1575;&#1606;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1578;&#1608;&#1601;&#1575;&#1604;&#1608;\">&#1578;&#1608;&#1601;&#1575;&#1604;&#1608;<\/option><option value=\"&#1571;&#1608;&#1594;&#1606;&#1583;&#1575;\">&#1571;&#1608;&#1594;&#1606;&#1583;&#1575;<\/option><option value=\"&#1571;&#1608;&#1603;&#1585;&#1575;&#1606;&#1610;&#1575;\">&#1571;&#1608;&#1603;&#1585;&#1575;&#1606;&#1610;&#1575;<\/option><option value=\"&#1575;&#1604;&#1573;&#1605;&#1575;&#1585;&#1575;&#1578; &#1575;&#1604;&#1593;&#1585;&#1576;&#1610;&#1577; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577;\">&#1575;&#1604;&#1573;&#1605;&#1575;&#1585;&#1575;&#1578; &#1575;&#1604;&#1593;&#1585;&#1576;&#1610;&#1577; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577;<\/option><option value=\"&#1575;&#1604;&#1605;&#1605;&#1604;&#1603;&#1577; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577;\">&#1575;&#1604;&#1605;&#1605;&#1604;&#1603;&#1577; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577;<\/option><option value=\"&#1575;&#1604;&#1608;&#1604;&#1575;&#1610;&#1575;&#1578; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577; &#1575;&#1604;&#1571;&#1605;&#1585;&#1610;&#1603;&#1610;&#1577;\">&#1575;&#1604;&#1608;&#1604;&#1575;&#1610;&#1575;&#1578; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577; &#1575;&#1604;&#1571;&#1605;&#1585;&#1610;&#1603;&#1610;&#1577;<\/option><option value=\"&#1571;&#1608;&#1585;&#1608;&#1594;&#1608;&#1575;&#1610;\">&#1571;&#1608;&#1585;&#1608;&#1594;&#1608;&#1575;&#1610;<\/option><option value=\"&#1571;&#1608;&#1586;&#1576;&#1603;&#1587;&#1578;&#1575;&#1606;\">&#1571;&#1608;&#1586;&#1576;&#1603;&#1587;&#1578;&#1575;&#1606;<\/option><option value=\"&#1601;&#1575;&#1606;&#1608;&#1575;&#1578;&#1608;\">&#1601;&#1575;&#1606;&#1608;&#1575;&#1578;&#1608;<\/option><option value=\"&#1605;&#1583;&#1610;&#1606;&#1577; &#1575;&#1604;&#1601;&#1575;&#1578;&#1610;&#1603;&#1575;&#1606;\">&#1605;&#1583;&#1610;&#1606;&#1577; &#1575;&#1604;&#1601;&#1575;&#1578;&#1610;&#1603;&#1575;&#1606;<\/option><option value=\"&#1601;&#1606;&#1586;&#1608;&#1610;&#1604;&#1575;\">&#1601;&#1606;&#1586;&#1608;&#1610;&#1604;&#1575;<\/option><option value=\"&#1601;&#1610;&#1578;&#1606;&#1575;&#1605;\">&#1601;&#1610;&#1578;&#1606;&#1575;&#1605;<\/option><option value=\"&#1575;&#1604;&#1610;&#1605;&#1606;\">&#1575;&#1604;&#1610;&#1605;&#1606;<\/option><option value=\"&#1586;&#1575;&#1605;&#1576;&#1610;&#1575;\">&#1586;&#1575;&#1605;&#1576;&#1610;&#1575;<\/option><option value=\"&#1586;&#1610;&#1605;&#1576;&#1575;&#1576;&#1608;&#1610;\">&#1586;&#1610;&#1605;&#1576;&#1575;&#1576;&#1608;&#1610;<\/option><\/select><\/div><\/div><!-- .wpforms-field-container --><div class=\"wpforms-submit-container\"><input type=\"hidden\" name=\"wpforms[id]\" value=\"2447\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages\/16099\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-2447\" class=\"wpforms-submit\" data-alt-text=\"&#1573;&#1585;&#1587;&#1575;&#1604;...\" data-submit-text=\"&#1573;&#1585;&#1587;&#1575;&#1604;\" aria-live=\"assertive\" value=\"wpforms-submit\">&#1573;&#1585;&#1587;&#1575;&#1604;<\/button><img decoding=\"async\" src=\"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/wpforms\/assets\/images\/submit-spin.svg\" class=\"wpforms-submit-spinner\" style=\"display: none;\" width=\"26\" height=\"26\" alt=\"Loading\" title=\"\"><\/div><\/form><\/div>  <!-- .wpforms-container --><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-138d73f0 e-flex e-con-boxed e-con e-parent\" data-id=\"138d73f0\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7f19437 elementor-widget elementor-widget-heading\" data-id=\"7f19437\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1575;&#1604;&#1578;&#1593;&#1604;&#1610;&#1605;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a83b8ed elementor-widget elementor-widget-text-editor\" data-id=\"a83b8ed\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>1994 - 1999 &#1575;&#1604;&#1578;&#1582;&#1589;&#1589; &#1601;&#1610; &#1575;&#1604;&#1591;&#1576;\n&#1580;&#1575;&#1605;&#1593;&#1577; &#1583;&#1608;&#1603;&#1608;&#1586; &#1573;&#1610;&#1604;&#1608;&#1604;&#1548; &#1603;&#1604;&#1610;&#1577; &#1575;&#1604;&#1591;&#1576;&#1548; &#1578;&#1585;&#1603;&#1610;&#1575;\n\n<\/li><li>1986 - 1992 &#1583;&#1585;&#1580;&#1577; &#1575;&#1604;&#1576;&#1603;&#1575;&#1604;&#1608;&#1585;&#1610;&#1608;&#1587;\n&#1580;&#1575;&#1605;&#1593;&#1577; &#1583;&#1608;&#1603;&#1608;&#1586; &#1573;&#1610;&#1604;&#1608;&#1604;&#1548; &#1603;&#1604;&#1610;&#1577; &#1575;&#1604;&#1591;&#1576;&#1548; &#1578;&#1585;&#1603;&#1610;&#1575;\t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ea8358b elementor-widget elementor-widget-heading\" data-id=\"ea8358b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1575;&#1604;&#1571;&#1606;&#1588;&#1591;&#1577; &#1601;&#1610; &#1575;&#1604;&#1605;&#1580;&#1604;&#1575;&#1578; &#1575;&#1604;&#1593;&#1604;&#1605;&#1610;&#1577;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bc0544f elementor-widget elementor-widget-text-editor\" data-id=\"bc0544f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>2021 - &#1605;&#1580;&#1604;&#1577; &#1571;&#1576;&#1581;&#1575;&#1579; &#1575;&#1604;&#1578;&#1589;&#1604;&#1576; &#1575;&#1604;&#1605;&#1578;&#1593;&#1583;&#1583; &#1575;&#1604;&#1580;&#1575;&#1585;&#1610;&#1577;\n&#1585;&#1574;&#1610;&#1587; &#1578;&#1581;&#1585;&#1610;&#1585; &#1605;&#1580;&#1604;&#1577; &#1571;&#1576;&#1581;&#1575;&#1579; &#1575;&#1604;&#1578;&#1589;&#1604;&#1576; &#1575;&#1604;&#1605;&#1578;&#1593;&#1583;&#1583; \t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6775816 elementor-widget elementor-widget-heading\" data-id=\"6775816\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1575;&#1604;&#1593;&#1590;&#1608;&#1610;&#1575;&#1578;\/&#1575;&#1604;&#1605;&#1606;&#1575;&#1589;&#1576; &#1601;&#1610; &#1575;&#1604;&#1605;&#1606;&#1592;&#1605;&#1575;&#1578; &#1575;&#1604;&#1593;&#1604;&#1605;&#1610;&#1577;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0a3c38 elementor-widget elementor-widget-text-editor\" data-id=\"d0a3c38\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>1999 - &#1605;&#1587;&#1578;&#1605;&#1585; &#1601;&#1610; &#1575;&#1604;&#1580;&#1605;&#1593;&#1610;&#1577; &#1575;&#1604;&#1578;&#1585;&#1603;&#1610;&#1577; &#1604;&#1604;&#1571;&#1605;&#1585;&#1575;&#1590; &#1575;&#1604;&#1593;&#1589;&#1576;&#1610;&#1577;\n&#1593;&#1590;&#1608; &#1601;&#1610; &#1575;&#1604;&#1580;&#1605;&#1593;&#1610;&#1577; &#1575;&#1604;&#1578;&#1585;&#1603;&#1610;&#1577; &#1604;&#1604;&#1571;&#1605;&#1585;&#1575;&#1590; &#1575;&#1604;&#1593;&#1589;&#1576;&#1610;&#1577; \t\t\t\t\t\t\t\t<\/li><\/ul><\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9cb9ae8 elementor-widget elementor-widget-heading\" data-id=\"9cb9ae8\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1571;&#1606;&#1588;&#1591;&#1577; &#1575;&#1604;&#1605;&#1588;&#1575;&#1585;&#1603;&#1577; &#1601;&#1610; &#1575;&#1604;&#1605;&#1572;&#1578;&#1605;&#1585;&#1575;&#1578; &#1608;&#1575;&#1604;&#1606;&#1583;&#1608;&#1575;&#1578;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6d86502 elementor-widget elementor-widget-text-editor\" data-id=\"6d86502\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>&#1606;&#1608;&#1601;&#1605;&#1576;&#1585; 12, 2022 &#1606;&#1608;&#1601;&#1605;&#1576;&#1585; 12, 2022 - &#1606;&#1608;&#1601;&#1605;&#1576;&#1585; 13, 2022 &#1575;&#1604;&#1606;&#1583;&#1608;&#1577; &#1575;&#1604;&#1587;&#1575;&#1576;&#1593;&#1577; &#1581;&#1608;&#1604; &#1575;&#1604;&#1573;&#1583;&#1585;&#1575;&#1603; &#1601;&#1610; &#1575;&#1604;&#1578;&#1589;&#1604;&#1576; &#1575;&#1604;&#1605;&#1578;&#1593;&#1583;&#1583;<br>&#1605;&#1583;&#1610;&#1585; &#1575;&#1604;&#1580;&#1604;&#1587;&#1577;<p>&#1573;&#1586;&#1605;&#1610;&#1585;&#1548; &#1578;&#1585;&#1603;&#1610;&#1575;<\/p><\/li><li>&#1571;&#1603;&#1578;&#1608;&#1576;&#1585; 26, 2022 - &#1571;&#1603;&#1578;&#1608;&#1576;&#1585; 28, 2022 ECTRIMS 2022<br>&#1605;&#1588;&#1575;&#1585;&#1603;<p>&#1571;&#1605;&#1587;&#1578;&#1585;&#1583;&#1575;&#1605;&#1548; &#1607;&#1608;&#1604;&#1606;&#1583;&#1575;<\/p><\/li><li>&#1610;&#1608;&#1606;&#1610;&#1608; 25&#1548; &#1610;&#1608;&#1606;&#1610;&#1608; 2022 - &#1610;&#1608;&#1606;&#1610;&#1608; 28&#1548; &#1610;&#1608;&#1606;&#1610;&#1608; 2022 &#1605;&#1572;&#1578;&#1605;&#1585; &#1575;&#1604;&#1588;&#1576;&#1603;&#1577; &#1575;&#1604;&#1571;&#1608;&#1585;&#1608;&#1576;&#1610;&#1577; &#1604;&#1604;&#1605;&#1604;&#1603;&#1610;&#1577; &#1575;&#1604;&#1601;&#1603;&#1585;&#1610;&#1577;<br>&#1605;&#1588;&#1575;&#1585;&#1603;<p>&#1601;&#1610;&#1610;&#1606;&#1575;&#1548; &#1575;&#1604;&#1606;&#1605;&#1587;&#1575;<\/p><\/li><li>&#1605;&#1575;&#1610;&#1608; 18, 2022 &#1605;&#1575;&#1610;&#1608; 18, 2022 - &#1605;&#1575;&#1610;&#1608; 19, 2022 IMSCOGS 2022<br>&#1605;&#1588;&#1575;&#1585;&#1603;<p>&#1576;&#1608;&#1585;&#1583;&#1608;&#1548; &#1601;&#1585;&#1606;&#1587;&#1575;<\/p><\/li><li>&#1571;&#1576;&#1585;&#1610;&#1604; 02, 2022 - &#1571;&#1576;&#1585;&#1610;&#1604; 07, 2022 &#1571;&#1576;&#1585;&#1610;&#1604; 2022 AAN 2022<br>&#1605;&#1588;&#1575;&#1585;&#1603;<p>&#1608;&#1575;&#1588;&#1606;&#1591;&#1606;&#1548; &#1575;&#1604;&#1608;&#1604;&#1575;&#1610;&#1575;&#1578; &#1575;&#1604;&#1605;&#1578;&#1581;&#1583;&#1577; &#1575;&#1604;&#1571;&#1605;&#1585;&#1610;&#1603;&#1610;&#1577;<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-034f82f elementor-widget elementor-widget-heading\" data-id=\"034f82f\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">&#1575;&#1604;&#1571;&#1576;&#1581;&#1575;&#1579;<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a06971 elementor-widget elementor-widget-text-editor\" data-id=\"2a06971\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t&lt;ul&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)&lt;\/strong&gt;\n    &lt;br&gt;Authors: &#350;en S., K&Uuml;RT&Uuml;NC&Uuml; M., Demir S., G&Uuml;ND&Uuml;Z T., Demirel E., T&uuml;t&uuml;nc&uuml; M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of the synchronized telerehabilitation-based upper extremity training program on hand-arm functions in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Dastan S., ERTEK&#304;N &Ouml;., &Ouml;zdo&#287;ar A. T., Kahraman T., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of Telerehabilitation-Based Motor Imagery Training on Pain and Related Factors in People With Multiple Sclerosis: Randomized Controlled Pilot Trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Karakas H., Kahraman T., &Ouml;zdo&#287;ar A. T., Baba C., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Toscano S., Spelman T., Ozakbas S., Alroughani R., Chisari C. G., Lo Fermo S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prevalence and Magnitude of Perceived Dual-Task Difficulties in People With Multiple Sclerosis: An International Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abas&#305;yan&#305;k Z., Pedull&agrave; L., Kahraman T., Soler B., Santoyo-Medina C., Tacchino A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2025\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The relationship between work difficulties and physical disability, cognitive and social cognitive impairment and subcortical gray matter atrophy in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Aslan T., &Ouml;zdo&#287;ar A. T., Sagici O., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Sharmin S., Malpas C., &Ouml;ZAKBA&#350; S., Lechner-Scott J., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Investigation of the Relationship Between Coping With the Disease and Afecting Cognitive, Physical, and Psychosocial Factors in People with Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sagici O., &Ouml;ZDO&#286;AR A. T., Aslan T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ccedil;EL&#304;K M., Baba C., IRMAK &Ccedil;., &Ouml;zbakba&#351; S., AVKAN O&#286;UZ V.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Signori A., Ponzano M., Kalincik T., &Ouml;ZAKBA&#350; S., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Predictors of relapse severity in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Abasiyanik Z., Simsek Y., Ozdogar A. T., Sagici O., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cognition as a parameter in monitoring the effect of multiple sclerosis relapse treatment: A prospective controlled study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Piri Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Yavas I., SAMADZADE U., &Ouml;ZDO&#286;AR A. T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Baba C., Yavas I., SAMADZADE U., &Ouml;ZDO&#286;AR A. T.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Levitz D., Chao Foong Y., Sanfilippo P., Spelman T., Rath L., Roldan A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Investigating the relationship of theory of mind and empathy with neuroimaging, neuropsychological, and neuropsychiatric data in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Aslan T., &Ouml;ZDO&#286;AR A. T., Sagici O., Yigit P., Zorlu N., BORA &#304;. E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies&lt;\/strong&gt;\n    &lt;br&gt;Authors: Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2024\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Risk of secondary progressive multiple sclerosis after early worsening of disability&lt;\/strong&gt;\n    &lt;br&gt;Authors: Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Dual-task difficulties as a risk factor for unemployment in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., Temiz H., Abasiyanik Z., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The risk of secondary progressive multiple sclerosis is geographically determined but modifiable&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Roos I., Simpson-Yap S., Malpas C., S&aacute;nchez M. M., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Tuncer A., Terzi M., B&Uuml;N&Uuml;L S. D., Ozen-Acar P., Altunrende B., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Feasibility of Telerehabilitation-Based Pelvic Floor Muscle Training for Urinary Incontinence in People With Multiple Sclerosis: A Randomized, Controlled, Assessor-Blinded Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yavas I., Kahraman T., Sagici O., Ozdogar A. T., Yigit P., Baba C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability accrual in primary and secondary progressive multiple sclerosis.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Hughes S., McDonnell G., Malpas C. B., Sharmin S., BOZ C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., &Ouml;ZAKBA&#350; S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhu C., Kalincik T., Horakova D., Zhou Z., Buzzard K., Skibina O., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity&mdash;Does it matter?&lt;\/strong&gt;\n    &lt;br&gt;Authors: T&uuml;t&uuml;nc&uuml; M., Demir S., Arslan G., Din&ccedil; &Ouml;., &#350;en S., G&Uuml;ND&Uuml;Z T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Daruwalla C., Shaygannejad V., &Ouml;ZAKBA&#350; S., Havrdova E. K., Horakova D., Alroughani R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: BOZ C., &Ouml;ZAKBA&#350; S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Narrative review based on fingolimod therapy in pediatric MS.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Piri Cinar B., Konuskan B., Anlar B., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects of prolonged walking on dual-task walking performance in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Veldkamp R., ERTEK&#304;N &Ouml;., Kalron A., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Psychometric properties of three self-report questionnaires assessing dual-task difficulties in people with multiple sclerosis: A multicenter study within the RIMS network&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Pedulla L., Kahraman T., D&rsquo;Hooge M., Santoyo-Medina C., Soler B., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association between work-related difficulties and dual-task ability in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Temiz H., Kahraman T., Abasiyanik Z., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness in multiple sclerosis: A methodological comparison&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., &Ouml;ZAKBA&#350; S., Alroughani R., TERZ&#304; M., Hodgkinson S., Laureys G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Ertekin &Ouml;., Kahraman T., Dastan S., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity&lt;\/strong&gt;\n    &lt;br&gt;Authors: Spelman T., Horakova D., &Ouml;ZAKBA&#350; S., Alroughani R., Onofrj M., Kalincik T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network&lt;\/strong&gt;\n    &lt;br&gt;Authors: Signori A., Lorscheider J., Vukusic S., Trojano M., Iaffaldano P., Hillert J., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Preference-Based Multiple Sclerosis Index: an assessment of its psychometric properties and translation into Turkish&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., Ozdogar A. T., Abasiyanik Z., Sagici O., Baba C., Ertekin &Ouml;., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COV&#304;D-19 in Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: &#350;en S., Arslan G., T&uuml;t&uuml;nc&uuml; M., Demir S., Din&ccedil; &Ouml;., G&Uuml;ND&Uuml;Z T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2023\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Ozcelik S., Kaya E., Samedzada U., Ozdogar A. T., Cevik S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Ozdogar A. T., &Ouml;Z&Ccedil;EL&#304;K S., KAYA E., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Factors related to restless leg syndrome in neuromyelitis optica spectrum disorder&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., KAYA E., Sagici O., Dastan S., Karakas H., Baba C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Predictive ability of the original and short form of the activities-specific balance confidence scale and its individual items for falls in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Baba C., Sagici O., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.&lt;\/strong&gt;\n    &lt;br&gt;Authors: Olmez O., Baba C., Abasiyanik Z., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Confirmed disability progression as a marker of permanent disability in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects and safety of exergaming in persons with multiple sclerosis during corticosteroid treatment: a pilot study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Baba C., Kahraman T., Sagici O., Dastan S., Ertekin &Ouml;., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Kaya E., Ozdogar A.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative Effectiveness and Persistence of Cladribine Tablets from GLIMPSE: Results from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Sustained attention during prolonged walking in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Veldkamp R., Ertekin &Ouml;., Kalron A., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar T., Sagici O., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., &Ccedil;&#304;NAR B. P., Baba C., Kosehasanogullari G.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Restless legs syndrome and related factors in people with multiple sclerosis in Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;zdo&#287;ar A. T., Ertekin &Ouml;., Kahraman T., Baba C., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Tuncer A., &Ouml;ZAKBA&#350; S., Uzunkopru C., Baba C., Demir S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;zakba&#351; S., Baba C., Do&#287;an Y., Cevik S., &Ouml;z&ccedil;elik S., Kaya E.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Fatigue is associated with physical inactivity in people with multiple sclerosis despite different environmental backgrounds: Merging and comparing cohorts from Turkey and Israel&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZDO&#286;AR A. T., Kahraman T., &Ouml;ZAKBA&#350; S., Achiron A., Kalron A.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic&lt;\/strong&gt;\n    &lt;br&gt;Authors: Baba C., Yigit P., Dastan S., Hancer P., Sagici O., &Ouml;ZAKBA&#350; S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2022\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Simpson-Yap S., De Brouwer E., Kalincik T., Rijke N., Hillert J. A., Walton C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018&lt;\/strong&gt;\n    &lt;br&gt;Authors: Moradi N., Sharmin S., Malpas C., &Ouml;ZAKBA&#350; S., Shaygannejad V., TERZ&#304; M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effect of exergaming in persons with multiple sclerosis with restless legs syndrome: a randomized controlled trial&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozdogar A. T., Ertekin O., Kahraman T., Aslan A. T., Dastan S., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparatve effectveness of beta-nterferons and glatramer acetate on physcal and cogntve functons: 6-month follow-up study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Aslan T., Abasiyanik Z., Ozdogar A. T.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Malpas C., Roos I., Diouf I., Alroughani R., Ozakbas S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yigit P., Sagici O., Abasiyanik Z., Baba C., Ozakbas S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;External validation of the MSBase model of individual treatment response (Crystal Ball 1.0)&lt;\/strong&gt;\n    &lt;br&gt;Authors: Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Terzi M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Ozakbas S., Boz C., Buzzard K., Skibina O., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Incidence and predisposing factors of COVID-19 in patients living with multiple sclerosis: Results from a prospective multiple sclerosis cohort&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Berktas M., Aslan T., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models&lt;\/strong&gt;\n    &lt;br&gt;Authors: Diouf I., Malpas C., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar A. T., Sagici O., Baba C.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Sharmin S., Ozakbas S., Horakova D., Havrdova E. K., Boz C., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relapse during the washout period predicts time to relapse after switching to cladribine&lt;\/strong&gt;\n    &lt;br&gt;Authors: Zhong M., van der Walt A., Hodgkinson S., Izquierdo G., Eichau S., Kalincik T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cognition as a parameter that should not be ignored when evaluating the effect of relapse treatment: A prospective controlled study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Real-world experience with cladribine in the MSBase Registry&lt;\/strong&gt;\n    &lt;br&gt;Authors: Butzkueven H., Spelman T., Hodgkinson S., Madueno S. E., Izquierdo G., Buzzard K., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Ozdogar A. T., Baba C., Ozcelik S., Kaya E.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., &Ouml;ZDO&#286;AR A. T., Abasiyanik Z., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Determinants of therapeutic lag in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Does the reason for the switch to fingolimod affect the treatment response?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Ozakbas S., Aslan T., Ozdogar A. T., Abasiyanik Z., Sagici O.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;A comparative study of the effects of yoga and clinical Pilates training on walking, cognition, respiratory functions, and quality of life in persons with multiple sclerosis: A quasi-experimental study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abas&#305;yan&#305;k Z., Yi&#287;it P., &Ouml;ZDO&#286;AR A. T., Kahraman T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Five-year real-world data on fingolimod treatment&rsquo;s effects on cognitive function&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., Piri Cinar B., Yigit P., Baba C., Sagici O.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression&lt;\/strong&gt;\n    &lt;br&gt;Authors: De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The effectiveness of natalizumab vs fingolimod&ndash;A comparison of international registry studies&lt;\/strong&gt;\n    &lt;br&gt;Authors: Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., S&oslash;rensen P. S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yigit P., A&ccedil;&#305;kg&ouml;z A., Mehdiyev Z., Day&#305; A., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sen S., Karabudak R., Schiavetti I., Demir S., Ozakbas S., Tutuncu M., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey&lt;\/strong&gt;\n    &lt;br&gt;Authors: Uzunkopru C., Tutuncu M., Gunduz T., G&Uuml;M&Uuml;&#350; H., Sen S., Demir S., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: ERTEK&#304;N &Ouml;., Kahraman T., Aras M., Baba C., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Validity and reliability of \"Cognitive Reserve Index Questionnaire\" for the Turkish Population&lt;\/strong&gt;\n    &lt;br&gt;Authors: &Ouml;ZAKBA&#350; S., Yigit P., Akyuz Z., Sagici O., Abasiyanik Z., &Ouml;ZDO&#286;AR A. T., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;High and low efficacy therapy in secondary progressive multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kahraman T., &Ouml;ZDO&#286;AR A. T., &Ouml;ZAKBA&#350; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study&lt;\/strong&gt;\n    &lt;br&gt;Authors: Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability Accrual in Primary Progressive &amp; Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Harding-Forrester S., Roos I., Sharmin S., Diouf I., Malpas C., Nguyen A., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability&lt;\/strong&gt;\n    &lt;br&gt;Authors: Abasiyanik Z., Kahraman T., Ertekin &Ouml;., Baba C., &Ouml;zakba&#351; S.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Delay from treatment start to full effect of immunotherapies for multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Roos I., Leray E., Frascoli F., Casey R., William Brown J., Horakova D., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts&lt;\/strong&gt;\n    &lt;br&gt;Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score&lt;\/strong&gt;\n    &lt;br&gt;Authors: Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.\n    &lt;br&gt;Citations: Unknown, Year: 2021\n  &lt;\/li&gt;\n  &lt;li&gt;&lt;strong&gt;Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis&lt;\/strong&gt;\n    &lt;br&gt;Authors: Minh Le M. L., Malpas C., Sharmin S., H\n    &lt;br&gt;Citations: Unknown, Year: Unknown\n  &lt;\/li&gt;\n&lt;li&gt;\n        &lt;strong&gt;Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study&lt;\/strong&gt;&lt;br&gt;\n        Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.&lt;br&gt;\n        Year: 2021 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a&lt;\/strong&gt;&lt;br&gt;\n        Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.&lt;br&gt;\n        Year: 2021 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Balance and Gait Impairment in Persons with Multiple Sclerosis with the Absence of Clinical Disability&lt;\/strong&gt;&lt;br&gt;\n        Ayan H., ERTEK&#304;N &Ouml;., Kahraman T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Delay from treatment start to full effect of immunotherapies for multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Explanatory factors of balance confidence in persons with multiple sclerosis: Beyond the physical functions&lt;\/strong&gt;&lt;br&gt;\n        Abasiyanik Z., &Ouml;zdo&#287;ar A. T., Sagici O., Kahraman T., Baba C., Ertekin &Ouml;., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., Kahraman T., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early clinical markers of aggressive multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder&lt;\/strong&gt;&lt;br&gt;\n        Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZ&#304; M., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The effects of Clinical Pilates training on walking, balance, fall risk, respiratory, and cognitive functions in persons with multiple sclerosis: A randomized controlled trial&lt;\/strong&gt;&lt;br&gt;\n        Abasiyanik Z., ERTEK&#304;N &Ouml;., Kahraman T., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Risk of secondary progressive multiple sclerosis: A longitudinal study&lt;\/strong&gt;&lt;br&gt;\n        Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.&lt;br&gt;\n        Year: 2020 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Determinant Role of Magnetic Resonance Imaging in Transition of Clinical Isolated Syndrome to Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        P&#304;R&#304; &Ccedil;&#304;NAR B., &Ouml;Z D., B&#304;RCAN KUR&#350;UN B., G&Uuml;RKAN M., &Ouml;ZT&Uuml;RK O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Determinant Role of Magnetic Resonance Imaging in Conversion from Clinically Isolated Syndrome to Multiple Sclerosis (Klinik &#304;zole Sendromda Multipl Skleroza D&ouml;n&uuml;&#351;&uuml;mde Manyetik Rezonans G&ouml;r&uuml;nt&uuml;lemenin Belirleyici Rol&uuml;)&lt;\/strong&gt;&lt;br&gt;\n        P&#304;R&#304; &Ccedil;&#304;NAR B., &Ouml;Z D., B&#304;RCAN KUR&#350;UN B., G&Uuml;RKAN M. A., &Ouml;ZT&Uuml;RK O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        BOZ C., TERZ&#304; M., Ozer B., Turkoglu R., KARABUDAK R., EFEND&#304; H., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of hormonal changes on the neurological status in the menstrual cycle of patient with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Yorgun Y. G., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., Honan C. A., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The 20-year history: Change of multiple sclerosis patient profile over 20 years&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., &Ccedil;&#304;NAR B. P., Kahraman T.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Oz D., Kosehasanogullari G., Kursun B. B., Kahraman T.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Frequency, type, distribution of pain and related factors in persons with multiple sclerosis'&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive involvement in clinically isolated syndrome and relationship with fatigue&lt;\/strong&gt;&lt;br&gt;\n        &Ccedil;&#304;NAR B. P., Yigit P., Gurkan M. A., Ozturk O., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.&lt;br&gt;\n        Year: 2019 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effects of cigarette smoking on respiratory problems and functional levels in multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Aktan R., &Ouml;ZALEVL&#304; S., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Relationship between Trunk Flexor Muscle Strength and Walking, Balance, and Falls in Multiple Sclerosis Patients (Multipl skleroz hastalar&#305;nda g&ouml;vde fleks&ouml;r kas kuvvetinin y&uuml;r&uuml;me,denge ve d&uuml;&#351;me ile ili&#351;kis)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Balance and Gait Disorder in Early Stages of Multiple Sclerosis (Multipl sklerozun erken evrelerinde denge ve y&uuml;r&uuml;y&uuml;&#351; bozuklu&#287;u)&lt;\/strong&gt;&lt;br&gt;\n        AYAN H., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Frequency, Type, Distribution of Pain and Related Factors in Individuals with Multiple Sclerosis (Multipl sklerozlu bireylerde a&#287;r&#305;n&#305;n s&#305;kl&#305;&#287;&#305;, tipi, da&#287;&#305;l&#305;m&#305; ve a&#287;r&#305;yla ili&#351;kili etmenler)&lt;\/strong&gt;&lt;br&gt;\n        KAHRAMAN T., &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Relationship between Respiratory Muscle Strength and Cognitive Functions in Multiple Sclerosis (Multipl sklerozda solunum kas kuvveti ile kognitif fonksiyonlararas&#305;nda ili&#351;ki)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., Y&#304;&#286;&#304;T P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effect of Clinical Pilates Training on Balance, Walking, Fall Risk, Respiratory Functions, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalar&#305;nda klinik Pilates e&#287;itiminin denge, y&uuml;r&uuml;me,d&uuml;&#351;me riski, solunum fonksiyonlar&#305; ve kognitif fonksiyonlar &uuml;zerineetkisi: randomize kontroll&uuml; &ccedil;al&#305;&#351;ma)&lt;\/strong&gt;&lt;br&gt;\n        ABASIYANIK Z., ERTEK&#304;N &Ouml;., KAHRAMAN T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Turkoglu R., Tamam Y., TERZ&#304; M., Taskapilioglu O., Y&Uuml;CESAN C., et al.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Smoking is associated with walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozdogar A., Kahraman T., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Long-term test-retest reliability and validity of the Six Spot Step Test in individuals with multiple sclerosis (Alt&#305; Nokta Ad&#305;m Testi&rsquo;nin multiple sklerozlu bireylerdeki uzun d&ouml;nem test-tekrar test uyum ve g&uuml;venirlili&#287;i)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;FEASIBILITY OF A 6-MONTH YOGA PROGRAM TO IMPROVE THE PHYSICAL AND PSYCHOSOCIAL STATUS OF PERSONS WITH MULTIPLE SCLEROSIS AND THEIR FAMILY MEMBERS&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., &Ouml;ZDO&#286;AR A. T., Yigit P., Hosgel I., Mehdiyev Z., ERTEK&#304;N &Ouml;., et al.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Upper Extremity Dysfunction in Multiple Sclerosis Patients without Clinical Disability (Klinik &ouml;z&uuml;r&uuml; olmayan Multipl skleroz hastalar&#305;nda &uuml;st ekstremite fonksiyon bozuklu&#287;u)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Restless Legs Syndrome and Related Factors in Multiple Sclerosis Patients (Multipl sklerozlu hastalar&#305;nda huzursuz bacak sendromu ve ili&#351;kili fakt&ouml;rler)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., KAHRAMAN T., Y&#304;&#286;&#304;T P., HO&#350;GEL &#304;., ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effect of Video Game Based Physical Activity Approach on Upper Extremity Function, Walking, Balance, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalar&#305;nda video oyunlari temelli fiziksel aktivite yakla&#351;&#305;m&#305;n&#305;n &uuml;st ekstremite fonksiyonu, y&uuml;r&uuml;me, denge ve kognitif fonksiyonlar &uuml;zerine etkisi: randomize kontroll&uuml; &ccedil;al&#305;&#351;ma)&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZDO&#286;AR A. T., ERTEK&#304;N &Ouml;., KAHRAMAN T., Y&#304;&#286;&#304;T P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2018 | Citation Count\/Metrics: Scopus\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Yigit P., Cinar B. P., Limoncu H., Kahraman T., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., KAYA &Ouml;Z&Ccedil;EL&#304;K P., Baser H., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;\"No evidence of disease activity - cognition\" in relapsing-remitting multiple sclerosis: recommendation for an extensive assessment of disease activity&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Yigit P., Kosehasanogullari G.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: SCI-Expanded\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., Kosehasanogullari G., Yigit P., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2017 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Social Cognition in Multiple Sclerosis: a Meta-Analysis&lt;\/strong&gt;&lt;br&gt;\n        BORA &#304;. E., &Ouml;ZAKBA&#350; S., Velakoulis D., Walterfang M.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., SAVCI S., Poyraz E. C., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Paced auditory serial addition test: National normative data&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., Cinar B. P., Gurkan M. A., Ozturk O., Oz D., Kursun B. B.&lt;br&gt;\n        Year: 2016 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Reassessment of Lhermitte&rsquo;s sign in multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        BECKMANN Y., &Ouml;ZAKBA&#350; S., Bulbul N. G., Kosehasanogullari G., SE&Ccedil;&#304;L Y., Bulut O., et al.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cognitive Impairment in Multiple Sclerosis: Historical Aspects, Current Status, and Beyond&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Determinants of physical activity in minimally impaired people with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Kahraman T., SAVCI S., Coskuner-Poyraz E., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too&lt;\/strong&gt;&lt;br&gt;\n        Kosehasanogullari G., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2015 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Uveitis associated with multiple sclerosis: complications and visual prognosis&lt;\/strong&gt;&lt;br&gt;\n        Kaya D., KAYA M., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Contingent Negative Variation Is Associated with Cognitive Dysfunction and Secondary Progressive Disease Course in Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        UYSAL U., Idiman F., Idiman E., &Ouml;ZAKBA&#350; S., Karakas S., Bruce J.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early Deterioration In Quality Of Life And Physical Functioning Of Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S., &#304;D&#304;MAN E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: Hakemli Dergi\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis.&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2014 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: Comparison of the results with that of multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Cinar B. P., &Ouml;ZAKBA&#350; S., Idiman E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Importance of neutralizing antibody positivity in Turkish multiple sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        KAYA D., TUFAN S., &Ouml;ZAKBA&#350; S., BAHAR H., ADA E., &#304;D&#304;MAN E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Sexual dysfunction in multiple sclerosis: Gender differences&lt;\/strong&gt;&lt;br&gt;\n        Celik D. B., Poyraz E. C., Bingol A., Idiman E., &Ouml;ZAKBA&#350; S., Kaya D.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Comparison of Physical Activity Status, Exercise Perception and Quality of Life Between Clinically Isolated Syndrome and Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Cinar B. P., ALGUN Z. C., Idiman E.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The Effects of Low and Severe Disability on Walking Abilities and Quality of Life in Multiple Sclerosis Patients: 6-Month Follow-up Study&lt;\/strong&gt;&lt;br&gt;\n        Ertekin &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E., ALGUN Z. C.&lt;br&gt;\n        Year: 2013 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging&lt;\/strong&gt;&lt;br&gt;\n        &Ouml;ZAKBA&#350; S., KAYA D., Idiman E.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Inflammatory demyelinating central nervous system diseases in childhood: Clinical and paraclinical profiles in 133 patients&lt;\/strong&gt;&lt;br&gt;\n        Kaya D., Idiman E., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Quality of Life, Fatigue and Balance Improvements after Home-Based Exercise Program in Multiple Sclerosis Patients&lt;\/strong&gt;&lt;br&gt;\n        ERTEK&#304;N &Ouml;., &Ouml;ZAKBA&#350; S., Idiman E., ALGUN Z. C.&lt;br&gt;\n        Year: 2012 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Symptomatic Menagement in Multiple Sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Effect of cognitive function and physical activity on the ability to learn and reproduce physiotherapy exercises in healthy subjects&lt;\/strong&gt;&lt;br&gt;\n        Kara B., GEN&Ccedil; A., Colakoglu B. D., &Ouml;ZAKBA&#350; S.&lt;br&gt;\n        Year: 2011 | Citation Count\/Metrics: SCI-Expanded\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;A Case of Fever of Unknown Origin: Co-existence of Kikuchi-Fujimoto Disease and Acute Disseminated Encephalomyelitis (ADEM)&lt;\/strong&gt;&lt;br&gt;\n        AVKAN O&#286;UZ V., Yapar N., &Ouml;ZAKBA&#350; S., Demir-Onder K., Aktas E., ALP &Ccedil;AVU&#350; S., et al.&lt;br&gt;\n        Year: 2010 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., &Ouml;zakba&#351; S., Do&#287;an Y., Kosehasanogullari G.&lt;br&gt;\n        Year: 2009 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Akdede B. B., Kosehasanogullari G., Aksan O., Idiman E.&lt;br&gt;\n        Year: 2007 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Idiman E., Yulug B., Pakoz B., Bahar H., Gulay Z.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in Multiple Sclerosis patients&lt;\/strong&gt;&lt;br&gt;\n        Yozbatiran N., Baskurt F., Baskurt Z., Ozakbas S., Idiman E.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample&lt;\/strong&gt;&lt;br&gt;\n        Idiman E., Uzunel F., Ozakbas S., Yozbatiran N., Oguz M., Callioglu B., et al.&lt;br&gt;\n        Year: 2006 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Ormeci B., Idiman E.&lt;br&gt;\n        Year: 2005 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Intrathecal sICAM-1 production in multiple sclerosis - Correlation with triple dose Gd-DTPA MRI enhancement and IgG index&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Idiman F., Kirkali G., Ozakbas S., Oktay G., Cakmakci H., et al.&lt;br&gt;\n        Year: 2005 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Ozakbas S., Cakmakci H., Idiman F., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features&lt;\/strong&gt;&lt;br&gt;\n        Donmez B., Ozakbas S., Oktem M., Gedizlioglu M., Coker I., Genc A. A., et al.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Cagiran I., Ormeci B., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Ormeci B., Akdede B. B., ALPTEK&#304;N K., Idiman E.&lt;br&gt;\n        Year: 2004 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features&lt;\/strong&gt;&lt;br&gt;\n        Ozakbas S., Idiman E., Baklan B., Yulug B.&lt;br&gt;\n        Year: 2003 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n    &lt;li&gt;\n        &lt;strong&gt;Nitric oxide as an activity marker in multiple sclerosis&lt;\/strong&gt;&lt;br&gt;\n        Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., Ozakbas S.&lt;br&gt;\n        Year: 2003 | Citation Count\/Metrics: PlumX Metrics\n    &lt;\/li&gt;\n&lt;\/ul&gt;\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u0627\u0644\u0628\u0631\u0648\u0641\u064a\u0633\u0648\u0631 \u0633\u0631\u0643\u0627\u0646 \u0623\u0648\u0632\u0627\u0643\u0628\u0627\u0634<\/p>\n","protected":false},"author":3,"featured_media":16102,"parent":14368,"menu_order":51,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[277],"tags":[164],"class_list":["post-16099","page","type-page","status-publish","has-post-thumbnail","hentry","category-277","tag-164"],"rankMath":{"parentDomain":"medicalpointinternational.com","noFollowDomains":[],"noFollowExcludeDomains":[],"noFollowExternalLinks":false,"featuredImageNotice":"\u064a\u062c\u0628 \u0623\u0646 \u064a\u0643\u0648\u0646 \u062d\u062c\u0645 \u0627\u0644\u0635\u0648\u0631\u0629 \u0627\u0644\u0645\u0645\u064a\u0632\u0629 200 \u00d7 200 \u0628\u0643\u0633\u0644 \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644 \u0644\u064a\u062a\u0645 \u0627\u0644\u062a\u0642\u0627\u0637\u0647\u0627 \u0628\u0648\u0627\u0633\u0637\u0629 Facebook \u0648\u0645\u0648\u0627\u0642\u0639 \u0627\u0644\u062a\u0648\u0627\u0635\u0644 \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639\u064a \u0627\u0644\u0623\u062e\u0631\u0649.","pluginReviewed":false,"postSettings":{"linkSuggestions":true,"useFocusKeyword":false},"frontEndScore":false,"postName":"%d8%a7%d9%84%d8%a8%d8%b1%d9%88%d9%81%d9%8a%d8%b3%d9%88%d8%b1-%d8%b3%d8%b1%d9%83%d8%a7%d9%86-%d8%a3%d9%88%d8%b2%d8%a7%d9%83%d8%a8%d8%a7%d8%b4","permalinkFormat":"https:\/\/medicalpointinternational.com\/ar\/%pagename%\/","showLockModifiedDate":true,"assessor":{"focusKeywordLink":"https:\/\/medicalpointinternational.com\/wp-admin\/edit.php?focus_keyword=%focus_keyword%&post_type=%post_type%","hasTOCPlugin":true,"primaryTaxonomy":false,"serpData":{"title":"","description":"","focusKeywords":"","pillarContent":false,"canonicalUrl":"","breadcrumbTitle":"","advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":"","facebookHasOverlay":false,"facebookImageOverlay":"","facebookAuthor":"","twitterCardType":"","twitterUseFacebook":true,"twitterTitle":"","twitterDescription":"","twitterImage":"","twitterImageID":"","twitterHasOverlay":false,"twitterImageOverlay":"","twitterPlayerUrl":"","twitterPlayerSize":"","twitterPlayerStream":"","twitterPlayerStreamCtype":"","twitterAppDescription":"","twitterAppIphoneName":"","twitterAppIphoneID":"","twitterAppIphoneUrl":"","twitterAppIpadName":"","twitterAppIpadID":"","twitterAppIpadUrl":"","twitterAppGoogleplayName":"","twitterAppGoogleplayID":"","twitterAppGoogleplayUrl":"","twitterAppCountry":"","robots":{"index":true},"twitterAuthor":"\u0627\u0633\u0645 \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645","primaryTerm":0,"authorName":"Ali \u00d6zgen\u00e7","titleTemplate":"%title% %sep% %sitename%","descriptionTemplate":"%excerpt%","showScoreFrontend":true,"lockModifiedDate":false},"powerWords":[],"diacritics":{"A":"[\\u0041\\u24B6\\uFF21\\u00C0\\u00C1\\u00C2\\u1EA6\\u1EA4\\u1EAA\\u1EA8\\u00C3\\u0100\\u0102\\u1EB0\\u1EAE\\u1EB4\\u1EB2\\u0226\\u01E0\\u00C4\\u01DE\\u1EA2\\u00C5\\u01FA\\u01CD\\u0200\\u0202\\u1EA0\\u1EAC\\u1EB6\\u1E00\\u0104\\u023A\\u2C6F]","AA":"[\\uA732]","AE":"[\\u00C6\\u01FC\\u01E2]","AO":"[\\uA734]","AU":"[\\uA736]","AV":"[\\uA738\\uA73A]","AY":"[\\uA73C]","B":"[\\u0042\\u24B7\\uFF22\\u1E02\\u1E04\\u1E06\\u0243\\u0182\\u0181]","C":"[\\u0043\\u24B8\\uFF23\\u0106\\u0108\\u010A\\u010C\\u00C7\\u1E08\\u0187\\u023B\\uA73E]","D":"[\\u0044\\u24B9\\uFF24\\u1E0A\\u010E\\u1E0C\\u1E10\\u1E12\\u1E0E\\u0110\\u018B\\u018A\\u0189\\uA779]","DZ":"[\\u01F1\\u01C4]","Dz":"[\\u01F2\\u01C5]","E":"[\\u0045\\u24BA\\uFF25\\u00C8\\u00C9\\u00CA\\u1EC0\\u1EBE\\u1EC4\\u1EC2\\u1EBC\\u0112\\u1E14\\u1E16\\u0114\\u0116\\u00CB\\u1EBA\\u011A\\u0204\\u0206\\u1EB8\\u1EC6\\u0228\\u1E1C\\u0118\\u1E18\\u1E1A\\u0190\\u018E]","F":"[\\u0046\\u24BB\\uFF26\\u1E1E\\u0191\\uA77B]","G":"[\\u0047\\u24BC\\uFF27\\u01F4\\u011C\\u1E20\\u011E\\u0120\\u01E6\\u0122\\u01E4\\u0193\\uA7A0\\uA77D\\uA77E]","H":"[\\u0048\\u24BD\\uFF28\\u0124\\u1E22\\u1E26\\u021E\\u1E24\\u1E28\\u1E2A\\u0126\\u2C67\\u2C75\\uA78D]","I":"[\\u0049\\u24BE\\uFF29\\u00CC\\u00CD\\u00CE\\u0128\\u012A\\u012C\\u0130\\u00CF\\u1E2E\\u1EC8\\u01CF\\u0208\\u020A\\u1ECA\\u012E\\u1E2C\\u0197]","J":"[\\u004A\\u24BF\\uFF2A\\u0134\\u0248]","K":"[\\u004B\\u24C0\\uFF2B\\u1E30\\u01E8\\u1E32\\u0136\\u1E34\\u0198\\u2C69\\uA740\\uA742\\uA744\\uA7A2]","L":"[\\u004C\\u24C1\\uFF2C\\u013F\\u0139\\u013D\\u1E36\\u1E38\\u013B\\u1E3C\\u1E3A\\u0141\\u023D\\u2C62\\u2C60\\uA748\\uA746\\uA780]","LJ":"[\\u01C7]","Lj":"[\\u01C8]","M":"[\\u004D\\u24C2\\uFF2D\\u1E3E\\u1E40\\u1E42\\u2C6E\\u019C]","N":"[\\u004E\\u24C3\\uFF2E\\u01F8\\u0143\\u00D1\\u1E44\\u0147\\u1E46\\u0145\\u1E4A\\u1E48\\u0220\\u019D\\uA790\\uA7A4]","NJ":"[\\u01CA]","Nj":"[\\u01CB]","O":"[\\u004F\\u24C4\\uFF2F\\u00D2\\u00D3\\u00D4\\u1ED2\\u1ED0\\u1ED6\\u1ED4\\u00D5\\u1E4C\\u022C\\u1E4E\\u014C\\u1E50\\u1E52\\u014E\\u022E\\u0230\\u00D6\\u022A\\u1ECE\\u0150\\u01D1\\u020C\\u020E\\u01A0\\u1EDC\\u1EDA\\u1EE0\\u1EDE\\u1EE2\\u1ECC\\u1ED8\\u01EA\\u01EC\\u00D8\\u01FE\\u0186\\u019F\\uA74A\\uA74C]","OI":"[\\u01A2]","OO":"[\\uA74E]","OU":"[\\u0222]","P":"[\\u0050\\u24C5\\uFF30\\u1E54\\u1E56\\u01A4\\u2C63\\uA750\\uA752\\uA754]","Q":"[\\u0051\\u24C6\\uFF31\\uA756\\uA758\\u024A]","R":"[\\u0052\\u24C7\\uFF32\\u0154\\u1E58\\u0158\\u0210\\u0212\\u1E5A\\u1E5C\\u0156\\u1E5E\\u024C\\u2C64\\uA75A\\uA7A6\\uA782]","S":"[\\u0053\\u24C8\\uFF33\\u1E9E\\u015A\\u1E64\\u015C\\u1E60\\u0160\\u1E66\\u1E62\\u1E68\\u0218\\u015E\\u2C7E\\uA7A8\\uA784]","T":"[\\u0054\\u24C9\\uFF34\\u1E6A\\u0164\\u1E6C\\u021A\\u0162\\u1E70\\u1E6E\\u0166\\u01AC\\u01AE\\u023E\\uA786]","TZ":"[\\uA728]","U":"[\\u0055\\u24CA\\uFF35\\u00D9\\u00DA\\u00DB\\u0168\\u1E78\\u016A\\u1E7A\\u016C\\u00DC\\u01DB\\u01D7\\u01D5\\u01D9\\u1EE6\\u016E\\u0170\\u01D3\\u0214\\u0216\\u01AF\\u1EEA\\u1EE8\\u1EEE\\u1EEC\\u1EF0\\u1EE4\\u1E72\\u0172\\u1E76\\u1E74\\u0244]","V":"[\\u0056\\u24CB\\uFF36\\u1E7C\\u1E7E\\u01B2\\uA75E\\u0245]","VY":"[\\uA760]","W":"[\\u0057\\u24CC\\uFF37\\u1E80\\u1E82\\u0174\\u1E86\\u1E84\\u1E88\\u2C72]","X":"[\\u0058\\u24CD\\uFF38\\u1E8A\\u1E8C]","Y":"[\\u0059\\u24CE\\uFF39\\u1EF2\\u00DD\\u0176\\u1EF8\\u0232\\u1E8E\\u0178\\u1EF6\\u1EF4\\u01B3\\u024E\\u1EFE]","Z":"[\\u005A\\u24CF\\uFF3A\\u0179\\u1E90\\u017B\\u017D\\u1E92\\u1E94\\u01B5\\u0224\\u2C7F\\u2C6B\\uA762]","a":"[\\u0061\\u24D0\\uFF41\\u1E9A\\u00E0\\u00E1\\u00E2\\u1EA7\\u1EA5\\u1EAB\\u1EA9\\u00E3\\u0101\\u0103\\u1EB1\\u1EAF\\u1EB5\\u1EB3\\u0227\\u01E1\\u00E4\\u01DF\\u1EA3\\u00E5\\u01FB\\u01CE\\u0201\\u0203\\u1EA1\\u1EAD\\u1EB7\\u1E01\\u0105\\u2C65\\u0250]","aa":"[\\uA733]","ae":"[\\u00E6\\u01FD\\u01E3]","ao":"[\\uA735]","au":"[\\uA737]","av":"[\\uA739\\uA73B]","ay":"[\\uA73D]","b":"[\\u0062\\u24D1\\uFF42\\u1E03\\u1E05\\u1E07\\u0180\\u0183\\u0253]","c":"[\\u0063\\u24D2\\uFF43\\u0107\\u0109\\u010B\\u010D\\u00E7\\u1E09\\u0188\\u023C\\uA73F\\u2184]","d":"[\\u0064\\u24D3\\uFF44\\u1E0B\\u010F\\u1E0D\\u1E11\\u1E13\\u1E0F\\u0111\\u018C\\u0256\\u0257\\uA77A]","dz":"[\\u01F3\\u01C6]","e":"[\\u0065\\u24D4\\uFF45\\u00E8\\u00E9\\u00EA\\u1EC1\\u1EBF\\u1EC5\\u1EC3\\u1EBD\\u0113\\u1E15\\u1E17\\u0115\\u0117\\u00EB\\u1EBB\\u011B\\u0205\\u0207\\u1EB9\\u1EC7\\u0229\\u1E1D\\u0119\\u1E19\\u1E1B\\u0247\\u025B\\u01DD]","f":"[\\u0066\\u24D5\\uFF46\\u1E1F\\u0192\\uA77C]","g":"[\\u0067\\u24D6\\uFF47\\u01F5\\u011D\\u1E21\\u011F\\u0121\\u01E7\\u0123\\u01E5\\u0260\\uA7A1\\u1D79\\uA77F]","h":"[\\u0068\\u24D7\\uFF48\\u0125\\u1E23\\u1E27\\u021F\\u1E25\\u1E29\\u1E2B\\u1E96\\u0127\\u2C68\\u2C76\\u0265]","hv":"[\\u0195]","i":"[\\u0069\\u24D8\\uFF49\\u00EC\\u00ED\\u00EE\\u0129\\u012B\\u012D\\u00EF\\u1E2F\\u1EC9\\u01D0\\u0209\\u020B\\u1ECB\\u012F\\u1E2D\\u0268\\u0131]","j":"[\\u006A\\u24D9\\uFF4A\\u0135\\u01F0\\u0249]","k":"[\\u006B\\u24DA\\uFF4B\\u1E31\\u01E9\\u1E33\\u0137\\u1E35\\u0199\\u2C6A\\uA741\\uA743\\uA745\\uA7A3]","l":"[\\u006C\\u24DB\\uFF4C\\u0140\\u013A\\u013E\\u1E37\\u1E39\\u013C\\u1E3D\\u1E3B\\u017F\\u0142\\u019A\\u026B\\u2C61\\uA749\\uA781\\uA747]","lj":"[\\u01C9]","m":"[\\u006D\\u24DC\\uFF4D\\u1E3F\\u1E41\\u1E43\\u0271\\u026F]","n":"[\\u006E\\u24DD\\uFF4E\\u01F9\\u0144\\u00F1\\u1E45\\u0148\\u1E47\\u0146\\u1E4B\\u1E49\\u019E\\u0272\\u0149\\uA791\\uA7A5]","nj":"[\\u01CC]","o":"[\\u006F\\u24DE\\uFF4F\\u00F2\\u00F3\\u00F4\\u1ED3\\u1ED1\\u1ED7\\u1ED5\\u00F5\\u1E4D\\u022D\\u1E4F\\u014D\\u1E51\\u1E53\\u014F\\u022F\\u0231\\u00F6\\u022B\\u1ECF\\u0151\\u01D2\\u020D\\u020F\\u01A1\\u1EDD\\u1EDB\\u1EE1\\u1EDF\\u1EE3\\u1ECD\\u1ED9\\u01EB\\u01ED\\u00F8\\u01FF\\u0254\\uA74B\\uA74D\\u0275]","oi":"[\\u01A3]","ou":"[\\u0223]","oo":"[\\uA74F]","p":"[\\u0070\\u24DF\\uFF50\\u1E55\\u1E57\\u01A5\\u1D7D\\uA751\\uA753\\uA755]","q":"[\\u0071\\u24E0\\uFF51\\u024B\\uA757\\uA759]","r":"[\\u0072\\u24E1\\uFF52\\u0155\\u1E59\\u0159\\u0211\\u0213\\u1E5B\\u1E5D\\u0157\\u1E5F\\u024D\\u027D\\uA75B\\uA7A7\\uA783]","s":"[\\u0073\\u24E2\\uFF53\\u015B\\u1E65\\u015D\\u1E61\\u0161\\u1E67\\u1E63\\u1E69\\u0219\\u015F\\u023F\\uA7A9\\uA785\\u1E9B]","ss":"[\\u00DF]","t":"[\\u0074\\u24E3\\uFF54\\u1E6B\\u1E97\\u0165\\u1E6D\\u021B\\u0163\\u1E71\\u1E6F\\u0167\\u01AD\\u0288\\u2C66\\uA787]","tz":"[\\uA729]","u":"[\\u0075\\u24E4\\uFF55\\u00F9\\u00FA\\u00FB\\u0169\\u1E79\\u016B\\u1E7B\\u016D\\u00FC\\u01DC\\u01D8\\u01D6\\u01DA\\u1EE7\\u016F\\u0171\\u01D4\\u0215\\u0217\\u01B0\\u1EEB\\u1EE9\\u1EEF\\u1EED\\u1EF1\\u1EE5\\u1E73\\u0173\\u1E77\\u1E75\\u0289]","v":"[\\u0076\\u24E5\\uFF56\\u1E7D\\u1E7F\\u028B\\uA75F\\u028C]","vy":"[\\uA761]","w":"[\\u0077\\u24E6\\uFF57\\u1E81\\u1E83\\u0175\\u1E87\\u1E85\\u1E98\\u1E89\\u2C73]","x":"[\\u0078\\u24E7\\uFF58\\u1E8B\\u1E8D]","y":"[\\u0079\\u24E8\\uFF59\\u1EF3\\u00FD\\u0177\\u1EF9\\u0233\\u1E8F\\u00FF\\u1EF7\\u1E99\\u1EF5\\u01B4\\u024F\\u1EFF]","z":"[\\u007A\\u24E9\\uFF5A\\u017A\\u1E91\\u017C\\u017E\\u1E93\\u1E95\\u01B6\\u0225\\u0240\\u2C6C\\uA763]"},"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasRedirection":true,"hasBreadcrumb":true},"homeUrl":"https:\/\/medicalpointinternational.com\/ar\/","objectID":16099,"objectType":"post","locale":"ar","localeFull":"ar","overlayImages":{"play":{"name":"\u0623\u064a\u0642\u0648\u0646\u0629 \u0627\u0644\u062a\u0634\u063a\u064a\u0644","url":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","path":"\/home\/medicalpointint\/public_html\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","position":"middle_center"},"gif":{"name":"\u0623\u064a\u0642\u0648\u0646\u0629 GIF","url":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","path":"\/home\/medicalpointint\/public_html\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","position":"middle_center"}},"defautOgImage":"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2024\/12\/Medical-Point-International-Hospital-Empty-Pic.png","customPermalinks":true,"isUserRegistered":true,"autoSuggestKeywords":true,"connectSiteUrl":"https:\/\/rankmath.com\/auth?site=https%3A%2F%2Fmedicalpointinternational.com%2Far%2F&r=https%3A%2F%2Fmedicalpointinternational.com%2Far%2Fwp-json%2Fwp%2Fv2%2Fpages%2F16099%3Fnonce%3D088e94288a&pro=1","maxTags":100,"trendsIcon":"<svg viewBox=\"0 0 610 610\"><path d=\"M18.85,446,174.32,290.48l58.08,58.08L76.93,504a14.54,14.54,0,0,1-20.55,0L18.83,466.48a14.54,14.54,0,0,1,0-20.55Z\" style=\"fill:#4285f4\"\/><path d=\"M242.65,242.66,377.59,377.6l-47.75,47.75a14.54,14.54,0,0,1-20.55,0L174.37,290.43l47.75-47.75A14.52,14.52,0,0,1,242.65,242.66Z\" style=\"fill:#ea4335\"\/><polygon points=\"319.53 319.53 479.26 159.8 537.34 217.88 377.61 377.62 319.53 319.53\" style=\"fill:#fabb05\"\/><path d=\"M594.26,262.73V118.61h0a16.94,16.94,0,0,0-16.94-16.94H433.2a16.94,16.94,0,0,0-12,28.92L565.34,274.71h0a16.94,16.94,0,0,0,28.92-12Z\" style=\"fill:#34a853\"\/><rect width=\"610\" height=\"610\" style=\"fill:none\"\/><\/svg>","showScore":true,"siteFavIcon":"https:\/\/medicalpointinternational.com\/wp-content\/uploads\/2024\/12\/Medical-Point-International-Hospital-Empty-Pic-150x150.png","canUser":{"general":false,"advanced":false,"snippet":false,"social":false,"analysis":false,"analytics":false,"content_ai":false},"showKeywordIntent":true,"isPro":true,"is_front_page":false,"trendsUpgradeLink":"https:\/\/rankmath.com\/pricing\/?utm_source=Plugin&utm_medium=CE%20General%20Tab%20Trends&utm_campaign=WP","trendsUpgradeLabel":"\u062a\u0631\u0642\u064a\u0629","trendsPreviewImage":"https:\/\/medicalpointinternational.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/trends-preview.jpg","currentEditor":false,"homepageData":{"assessor":{"powerWords":[],"diacritics":true,"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasBreadcrumb":true,"serpData":{"title":"%sitename% %page% %sep% %sitedesc%","description":"","titleTemplate":"%sitename% %page% %sep% %sitedesc%","descriptionTemplate":"","focusKeywords":"","breadcrumbTitle":"\u0627\u0644\u0635\u0641\u062d\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","robots":{"index":true},"advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":""}}},"isAnalyticsConnected":false,"tocTitle":"Table of Contents","tocExcludeHeadings":[],"listStyle":"ul"},"_links":{"self":[{"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages\/16099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/comments?post=16099"}],"version-history":[{"count":8,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages\/16099\/revisions"}],"predecessor-version":[{"id":59291,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages\/16099\/revisions\/59291"}],"up":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/pages\/14368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/media\/16102"}],"wp:attachment":[{"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/media?parent=16099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/categories?post=16099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalpointinternational.com\/ar\/wp-json\/wp\/v2\/tags?post=16099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}